Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2013

Selection of a Non-Phosphorylated Peptide Inhibitor of BRCA1’s
(BRCT)2 Domain
Railey White
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medicine and Health Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/585

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Elizabeth Railey White
All Rights Reserved

2013

Selection of a Non-Phosphorylated Peptide Inhibitor of BRCA1’s (BRCT)2 Domain
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy (Chemical Biology)
at
Virginia Commonwealth University (2013)
By
ELIZABETH RAILEY WHITE
B.S. Chemistry (2007)
University of Kentucky, Lexington, KY

Advisor: Matthew C. T. Hartman, Ph.D.
Assistant Professor, Department Of Chemistry,
Virginia Commonwealth University,
Richmond, Virginia.
May, 2013

ii

Acknowledgment

My road getting here, and surviving once I did, has fortunately been filled with
supporters of many varieties, and without them I may not have arrived as sanely as I have, or
perhaps not at all. I’ll start with my family, who have encouraged me from day one, and
convinced me that I can do anything I put my mind to, even if it meant going along with my
plans as a five-year old to become either an archaeologist or a Ghostbuster. Without that sense
of spirit, I would have given up long ago. I also owe a lot to Dr. David Atwood who allowed me
to naively walk into his lab as a first semester freshman and who also casually mentioned one
day the MD/PhD program as a means to sway me from the “dark side” of medicine. I have great
appreciation for Lisa Blue and Trish Coakley who helped me grow up as a scientist, and for that
I will always be grateful.
The four years I’ve spent working toward this degree would have been far more difficult
if it hadn’t been for the amazing lab mates I’ve been fortunate enough to work with. Overall we
have had way more laughter and smiles than tears and frustration, and anyone who has received
a PhD knows that is a blessing we should all hope to be bestowed. I’ve had the great fortune of
working with Dr. Zhong Ma, Dr. Gajanan Dewkar, Dr. Tim Reed, Michael Dcona, Deboleena
Mitra, Sara Ahadi, Daniela Selaya, David Hacker, Jonathan Sheldon, and Brittany Danzig. Each
one of these individuals has helped me grow as a scientist, but more importantly made me laugh,
often times when I needed it most. My fellow graduate students have not just remained lab
mates, but have truly become my friends. In addition I must mention my Richmond family that

iii

always know when I need a run, a hug, a drink, or a round of “The Game of Life.” In particular
that means you Albéric Rogman, Hope Bailey, Sarah Vunck, Greg Hawkins and Chris Faigle.
My committee has been extremely helpful throughout this journey, and they have each
lent their own expertise to this work. I would like to thank Dr. Nicholas Farrell, Dr. Kris Valerie,
Dr. Vladimir Sidorov, and Dr. David Williams. I appreciate the help offered by the Department
of Chemistry and Massey Cancer Center. I also thank Altria and the Concern Foundation for
financial support.
Obviously, I owe many thanks to Dr. Hartman whose ideas and mentorship have forever
molded the way I will approach problems. I have to remind myself that most PhD candidates are
not as lucky as I have been to have such a well matched mentor. It really has been a pleasure.

iv

TABLE OF CONTENTS

List of Tables ................................................................................................................................ vi
List of Figures .............................................................................................................................. vii
Abstract ......................................................................................................................................... ix
Chapter 1. Introduction .................................................................................................................. 1
1.1 BRCA1 and Cancer ......................................................................................................1
1.1.1 BRCA1 Discovery ..................................................................................... 1
1.1.2 A DNA Repair Protein with Many Functions ........................................... 2
1.1.3 The Role of BRCA1 in the Clinical Prognosis of Cancer ......................... 3
1.1.4 Need for Inhibitors of BRCA1 .................................................................. 4
1.2 Peptides and Drug Development ................................................................................ 5
1.2.1 A Brief History of Drug Development ...................................................... 5
1.2.2 A New Role for Peptides in Drug Discovery ............................................ 6
1.3 Current Development of BRCA1 Inhibitors ............................................................... 7
1.3.1 Introduction ............................................................................................... 7
1.3.2 N-terminal RING Domain ......................................................................... 9
1.3.3 C-terminal (BRCT)2 Domain ................................................................... 10
1.3.4 PALB2 and SQ Domains ......................................................................... 11
1.4 Peptide Selection with Libraries ................................................................................ 12
1.4.1 Peptide Libraries: An Introduction .......................................................... 12
1.4.2 Immobilized Peptide Libraries: SPOT and OBOC .................................. 13
1.4.3 Cellular Display Techniques: Phage and Display .................................... 14
1.4.4 In vitro Display Techniques: mRNA and Ribosome Display .................. 15
1.4.5 Incorporation of UNAA in Translation .................................................... 18
1.4.6 Unnatural Peptide Library Selections ...................................................... 20
1.5 Characterization of Binding Affinities ....................................................................... 21
1.5.1 What is a Binding Affinity? ..................................................................... 21
1.5.2 Equilibrium Ultrafiltration Binding Assay .............................................. 22
1.5.3 Isothermal Titration Calorimetry (ITC) ................................................... 24
1.5.4 Fluorescence Polarization (FP) ................................................................ 29
1.5.5 Surface Plasmon Resonance (SPR) ......................................................... 32
1.5.6 Summary of Current Techniques ............................................................. 34
Chapter 2. Drug-Like Peptides: Unnatural Amino Acids ............................................................ 36
2.1 Introduction ................................................................................................................ 37
2.2 Testing Individual Amino Acids in Translation ........................................................ 40
2.3 Combination of UNAAs in PURE Translation ......................................................... 55
2.4 Testing UNAAs with Library Templates .................................................................. 55

v

2.5 Discussion ................................................................................................................. 59
2.6 Experimental ............................................................................................................. 60
2.7 Summary ................................................................................................................... 63
Chapter 3. Strength in Numbers: mRNA Display Library Selection Against BRCA1 (BRCT)2
……………………………………………………………………………………………………………………………………………………..64
3.1 Introduction ................................................................................................................ 65
3.2 Selection Preparation and Optimization .................................................................... 66
3.3 mRNA Display Library Selection Against BRCA1 (BRCT)2 ................................... 71
3.4 Sequencing ................................................................................................................ 74
3.5 Discussion ................................................................................................................. 74
3.6 Experimental ............................................................................................................. 74
3.7 Summary ................................................................................................................... 80
Chapter 4. Life After Sequencing: Ranking the Top Peptide Hits .............................................. 82
4.1 Introduction ................................................................................................................ 83
4.2 Equilibrium Ultrafiltration Binding Assay................................................................. 83
4.3 Surface Plasmon Resonance ..................................................................................... 85
4.4 Isothermal Titration Calorimetry .............................................................................. 91
4.5 MS/MS Analysis of Peptide Cyclization.................................................................... 92
4.6 Fluorescence Polarization ......................................................................................... 94
4.7 Discussion ................................................................................................................. 96
4.8 Experimental ............................................................................................................ 100
4.9 Summary ................................................................................................................. 105
Chapter 5. Where’s the Phosphate?: Investigation of Peptide 8.6 Binding Mechanism Through
Mutational Analysis ................................................................................................................... 107
5.1 Introduction .............................................................................................................. 108
5.2 Examination of Peptide 8.6 Truncation ................................................................... 108
5.3 Mutational Analysis of Peptide 8.6 .......................................................................... 110
5.4 Hybridization of Peptides 8.1 and 8.6 ..................................................................... 112
5.5 Examination of the Highest Affinity Peptides by ITC ............................................. 115
5.6 Inhibition of CtIP-BRCA1 Interaction in Cell Lysate ............................................. 119
5.7 Discussion................................................................................................................. 120
5.8 Experimental ............................................................................................................ 123
5.9 Summary .................................................................................................................. 126
Chapter 6. Overcoming Current Limitations: Expansion of DRaCALA to Peptides ................ 128
6.1 Introduction
....................................................................................................... 129
6.2 Diffusion of Peptides on Nitrocellulose ................................................................... 131
6.3 Model Systems for Comparison to Current Techniques .......................................... 131
6.4 Discussion ................................................................................................................ 134
6.5 Experimental ............................................................................................................ 136
6.6 Summary .................................................................................................................. 137
Overall Summary and Conclusions ........................................................................................... 139

vi

References .................................................................................................................................. 145
Appendix I MALDI-TOF Analysis of Peptides ......................................................................... 158
Appendix II Fluorescence Polarization Binding Curves ........................................................... 172
Vita ............................................................................................................................................. 185

vii

LIST OF TABLES
Chapter 1
1.1 Summary of Binding Affinity Techniques ................................................................ 35
Chapter 2
2.1 mRNA Test Templates .............................................................................................. 41
2.2 Final Concentration of Unnatural Amino Acids and PRS ......................................... 57
Chapter 4
4.1 Ranking of Peptides from Selection .......................................................................... 98
Chapter 5
5.1 Truncation Analysis of Peptide 8.6 .......................................................................... 109
5.2 Mutational Analysis of Peptide 8.6........................................................................... 111
5.3 Analysis of Hybridized Peptides .............................................................................. 114
5.4 Thermodynamic Values from ITC Analysis ............................................................ 117
5.5 Peptides Known to Bind to the (BRCT)2 Domain ................................................... 122
Chapter 6
6.1 Peptides Chosen to Test for Diffusion on Nitrocellulose ........................................ 132

viii

LIST OF FIGURES
Chapter 1
1.1 Potential BRCA1 Therapeutic Targets ........................................................................ 8
1.2 mRNA Display and Ribosome Display ..................................................................... 16
1.3 Equilibrium Ultrafiltration Binding Assay ................................................................ 23
1.4 Setup of Isothermal Titration Instrumentation ........................................................... 26
1.5 An Example ITC Isotherm ......................................................................................... 27
1.6 Fluorescence Polarization .......................................................................................... 30
1.7 Surface Plasmon Resonance Experiment with α-GST Antibody .............................. 33
Chapter 2
2.1 Incorporation of UNAA in PURE Translation by Substitution ................................. 38
2.2 UNAA Analogs .......................................................................................................... 39
2.3a Initial MALDI Analysis of UNAA in Translation ................................................... 42
2.3b Initial MALDI Analysis of UNAA in Translation Continued ................................. 43
2.4 Misincorporation Table .............................................................................................. 45
2.5 Titration of P1 Analogue in Translation ..................................................................... 47
2.6 V3 Incorporation with Deacylated tRNA ................................................................... 48
2.7 Titration of V3 Concentration with Deacylated tRNA ............................................... 50
2.8 Effect of Deacylated tRNA on Peptide Yield ............................................................ 51
2.9 Increased in Concentration to Improve W3 Fidelity .................................................. 52
2.10 Increased in TrpRS to Improve W3 Fidelity ............................................................ 52
2.11 Incorporation of Analogue I2 with High Amino Acid Concentration ...................... 53
2.12 Analogue I2 Deacylation Tests ................................................................................. 54
2.13 Translation with All Six UNAAs ............................................................................. 56
2.14 Yield of All 6 UNAAs with Library Templates ...................................................... 58
Chapter 3
3.1 Library Design ........................................................................................................... 67
3.2 SDS-PAGE Anlaysis of Purified Fusion ................................................................... 69
3.3 Elution of GST-(BRCT)2 Fusion from Glutathione Beads ........................................ 70
3.4 In vitro Selection Scheme .......................................................................................... 72
3.5 Selection Progress ...................................................................................................... 73
3.6 Selection Sequencing Results .................................................................................... 75
3.7 Family Sequence Alignment ...................................................................................... 76
Chapter 4
4.1 Equilibrium Ultrafiltration Binding Assay ................................................................ 84
4.2 PCR Amplification of Library cDNA ........................................................................ 86
4.3 SPR Experiment with α-GST Antibody ..................................................................... 89
4.4 SPR with Nuclear Localization Sequence ................................................................. 90
4.5 Initial ITC Data with NLS peptides ........................................................................... 93
4.6 Proposed Cyclization Structure .................................................................................. 95
4.7 SDS-PAGE Analysis of Purified Thioredoxin-(BRCT)2 Fusion Protein .................. 97

ix

Chapter 5
5.1 ITC Analysis of Highest Affinity Peptides .............................................................. 116
5.2 Inhibition of (BRCT)2 and CtIP Interaction in Cell Lysate..................................... 118
Chapter 6
6.1 DRaCALA Experiment ............................................................................................ 130
6.2 Test of Peptide Diffusion on Nitrocellulose ............................................................ 133
6.3 DRaCALA of 5-FAM-β-A-pSPTF. ......................................................................... 135

x

Abstract

SELECTION OF A NON-PHOSPHORYLATED PEPTIDE INHIBITOR
OF BRCA1’S (BRCT) DOMAIN

Elizabeth Railey White
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2013
Advisor: Matthew C. T. Hartman, PhD, Department of Chemistry
A growing body of literature suggests Breast Cancer-Associated Protein 1 (BRCA1) is
important not only as a cause, but also as a target in the quest for cancer treatment. BRCA1
deficient cells treated with radiation as well as PARP inhibitors and other chemotherapeutics
demonstrate a greater sensitivity than cells with wild type BRCA1. Inhibitors of BRCA1 would
take advantage of this synthetic lethality and represent a significant advance in cancer treatment
as well as an understanding of the biology of DNA repair. Despite significant study of BRCA1
protein and function, it is a large protein (220 KDa) that is still largely uncharacterized, but its Nand C-terminal domains have been described by significant structural data. The BRCT (BRCA1
C-Terminal) Domain is a phosphoprotein binding domain that is commonly mutated or lost in
cancers and has a binding cleft seemingly very suitable for drug design. Small molecule screens
have been conducted against this domain, but the resulting hits with moderate affinity have not
been shown to induce BRCA1 deficient phenotypes. Phosphopeptides have also been studied as
potential BRCA1 inhibitors, yet despite some having affinities in the mid-nanomolar range the
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presence of a phosphate is not without its pharmacologic challenges. We generated an mRNA
display library with 1.3 x 1013 cyclized peptides covalently attached to the mRNA that encoded
them. Eight rounds of selection exposing the library to a GST-BRCT fusion resulted in selection
of non-phosphorylated peptides that bind to a BRCT domain of BRCA1. The sequences
resulting from the selection have common homologies and initial characterization has shown that
these peptides may be the first viable non-phosphoserine containing inhibitors of BRCA1.

CHAPTER 1. INTRODUCTION

1.1 BRCA1 and Cancer
1.1.1 BRCA1 Discovery
The idea of a hereditary form of breast cancer was first put forth in a pedigree published
in 1866,1 but it would be more than 100 years later until the discovery that this syndrome had a
genetic basis in the form of a gene now known as the Breast Cancer Associated Protein 1
(BRCA1). After the initial Broca report in 1866, only a few similar familial studies were
published over the next 100 years.2 It wasn’t until the 1960’s that Henry Lynch began collecting
information from 120 families with hereditary breast and ovarian carcinomas creating the largest
cohort of its kind in the world which came to be known as the Creighton families.2 Through
genetic linkage studies in families with early-onset breast and ovarian carcinomas, King and
coworkers who named the protein were able to identify the location of the responsible BRCA1
gene to the long arm of chromosome 17.3 Applying this finding to the large sample size of the
Creighton families, the location of BRCA1 on the chromosome was identified and the gene was
cloned in 1994.4 Despite knowing the sequence of BRCA1 for nearly two decades, much of the
structure of BRCA1 has yet to be fully elucidated, and the functions of this important gene are
continuing to emerge.

1

1.1.2 A DNA Repair Protein with Many Functions
BRCA1 is a large protein, weighing in at 220 kDa.5 Shuttling between the nucleus and
cytoplasm, BRCA1 primarily acts as a scaffold protein forming many different complexes with
other proteins to respond to many cellular functions and DNA damage. Many of BRCA1’s 1863
amino acids have undetermined structure with the exception of the N-Terminal RING (Really
Interesting New Gene) domain, C-terminal BRCT (BRCA1 C-Terminal) domain, and the coiledcoil PALB2 (partner and localizer of BRCA2) binding domain. The BRCA1 RING domain is
constitutively bound to BARD1 as a heterodimer known as the core complex. This complex is
known to mediate E3 ubiquitin ligation.6 BRCT domains are found in many proteins that
respond to DNA damage.

Many, but not all BRCT domains are phosphoprotein binding

modules.7 The BRCT domain of BRCA1 is particularly important because of its many binding
partners that interact at various times depending on their phosphorylation status. The three major
BRCT binding partners are Abraxas (also known as CCDC98 and FAm175A), BACH1
(BRCA1-interacting protein C-terminal helicase 1, also known as FANJ and BRiP1), and CtIP
(CtBP-interacting protein, also known as RBBP8).8 The complexes that form with these three
proteins, BRCA1 as well as other associated proteins are named the BRCA1-A (Abraxas), -B
(BACH1), and -C (CtIP). Together these complexes are known to regulate control of the G2–M
checkpoint, BRCA1 accumulation at damage-induced foci, DNA replication, S-phase
progression, DNA resection, and G2–M checkpoint control.9 The interaction of PALB2 and
BRCA1 is known to be important to mediate homologous recombination (HR) repair of DNA,
but this mechanism remains unclear.9 Other evolutionarily conserved sequences throughout the
rest of BRCA1’s sequence imply that there are other important functions of this protein that have
yet to be discovered. Yet even with the small percentage of BRCA1 function currently known it
2

has still been dubbed the “master regulator of genomic integrity.”9 It is, therefore, no surprise
that deficiency of this important protein can lead to a predisposition to cancer.

1.1.3 The Role of BRCA1 in the Clinical Prognosis of Cancer
For a very long time, a careful family history was the only means of determining ones
risk for cancer. In the 1990’s genetic linkage studies were applied to risk assessment for high
risk families.2 Since then genetic counseling has progressed, and BRCA1 sequencing is now
commonly applied for individuals at risk. In addition non-sequence based BRCA1 deficiency
tests, such as the protein truncation test were adopted quickly after the gene was identified.10
Most BRCA1 testing is now done with direct gene sequencing, but the results of these tests are
providing more questions than answers with respect to risk assessment and management.11 In
addition to analysis of patient BRCA1 mutation carrier status, analysis of BRCA1 deficiency in
individual tumors can have a significant impact on prognosis and treatment options.12
BRCA1 is a tumor suppressor gene (TSG), and its deficiency results in a whole host of
cellular abnormalities. This is why inherited homozygous deficiency is embryonic lethal, and
why as a TSG under the two-hit hypothesis carriers of a single deficient copy of the gene are predisposed to developing cancer.13 However, studies of patients with BRCA1 deficient tumors
have revealed that they typically respond to DNA-damaging cancer therapies at a higher rate
than do patients with tumors expressing wild-type BRCA1.14 In the past few years, researchers
have begun discover the underlying mechanisms behind this observation, and have created new
therapies to exploit these insights. The most prevalent example of this are inhibitors of the
enzyme poly ADP ribose polymerase (PARP). PARP inhibitors (PARPi) prevent repair of
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double-stranded DNA (dsDNA) breaks via the non-homologous end joining (NHEJ) pathway.15
Because BRCA1 deficient cancer cells have aberrant homologous recombination repair (HRR)
of dsDNA breaks, they therefore become more reliant on NHEJ to repair these breaks.16 The
toxicity of PARPi on BRCA1 deficient cells is an example of synthetic lethality, and PARPi are
now being applied in the clinic as a much less toxic alternative to traditional cancer therapies in
patients with BRCA1 deficiencies.17

1.1.4 Need for Inhibitors of BRCA1
From what has been learned from patients with BRCA1 deficient tumors, it is easy to see
the implication that BRCA1 inhibitors could hold for cancer therapeutics. Application of lesstoxic drugs such as PARPi with a targeted BRCA1 inhibitor could be applied to many different
types of tumors regardless of BRCA1 status in order to mimic the BRCA1 deficiency that lends
itself so nicely to synthetic lethality based treatments. Another potential application for BRCA1
inhibitors would be to prevent PARPi resistance. Although tumors with BRCA1 mutations
respond well to treatment with PARPi, they can become resistant to the treatment.18 Because
tumors are heterogeneous and constantly evolving, it is no surprise that at least some of the cells
express wild-type BRCA1, or acquire a mutation that results in reversion back to wild-type.
Therefore combination of a PARPi or other therapeutics with a targeted BRCA1 inhibitor could
help prevent this resistance and further improve cancer treatment in the high-risk BRCA1positive populations. Additionally, despite the incredible amount of information that is known
about BRCA1’s functions, it is central to a large web of cellular interactions that is still far from
being untangled.

Site-specific, temporally controllable, and dosable inhibitors would be a
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complementary and valuable tool in further understanding BRCA1 function leading eventually to
better therapeutics not only for cancer but diseases that involve other BRCA1 related proteins
such as Fanconi Anemia.19

1.2 Peptides and Drug Development
1.2.1 A Brief History of Drug Development
Surviving ancient texts from China, Egypt, India, Greece and Rome describe remedies
for ailments of all sorts, but it was not until the 18th century that medicine progressed from herbal
remedies to seminal observations that became the birth of modern medicine.20 Jenner observed
in 1796 that a patient exposed to cow pox was subsequently immune to small pox leading to
development of the first vaccine. Preventative medicine has certainly been revolutionized by
vaccination, but arguably drugs have made an even larger impact on medicine.21 Advances in
analytical chemistry lead to significant advances such as the isolation of morphine from opium in
1815.22 However, at this time many of the foundations of chemical theory were still being
formed, so pharmacology developed as a field in its own right.21 By the 1930’s natural product
screening was the focus of drug development focused primarily on antibiotic discovery.21
In the 20th century, biological observations combined with advances in chemistry lead to
an explosion of efficacious drugs. However, as of the late 1990’s only about 500 molecular
targets were successfully targeted with drugs, and among these targets the majority were either
cell-membrane receptors, G-protein-coupled receptors or enzymes.23 Despite advances in drug
discovery techniques including combinatorial chemistry, and in silico based drug discovery, the
number of new drugs reaching the market has dramatically diminished over the past 20 years to
5

the point where large companies develop only a single approved new chemical entity each
year.24 The slowed productivity of the drug discovery pipeline has led to more interest in nontraditional targets. Among the promising new targets for drug discovery are protein-protein
interactions (PPIs), despite their previous label of ‘un-druggable.’

1.2.2 A New Role for Peptides in Drug Discovery
Attempts to map the interactome have detected thousands of previously unknown PPIs
and have only begun to brush the surface of this complicated network that governs the
proteome.25 The reason these interactions have been overlooked for drug design is they are often
flat and featureless26 and therefore not amenable to disruption by small molecules that have been
so successfully applied to the classic biding pockets found in enzymes and many other proteins.
More recent analysis of the surfaces of PPIs has shown that these surfaces are governed by more
than hydrophobic interactions and often have longer binding grooves or a series of “hot spots”
that combine to mediate the interaction.26 Despite this new perspective, PPIs often remain out of
reach for inhibition with traditional small molecules. This observation has led to attempts to
inhibit these interactions instead through protein mimetics, such as peptides.27 With their larger
size comes the ability to span the larger surface areas associated with PPIs which can often lead
to greater specificity than generally found with small molecule drugs. Despite the great potential
of peptides to act as inhibitors to a wealth of new drug targets in the form of PPIs, the idea of
such approaches has been met which much skepticism.
The criticism of peptides as drugs is due primarily to their inherent susceptibility to
protease degradation and lack of inherent cellular permeability, which would make them unlikely
6

drug candidates in the traditional sense. However, there are a surprising number of peptides and
peptide-derivatives found on the market today and many tools are being developed to overcome
remaining challenges.28 Many of these peptides mostly bind to extra-cellular targets, but with an
ever increasing number of methods for intracellular peptide delivery (such as CPPs,29 pHLIP,30
lipid31 and nano-particle32 based delivery systems), peptides are becoming even more viable
drugs to target PPIs. The issue of stability has been addressed in many simple ways including
the synthesis of retro-inverso, N-methylated, and stapled peptides. In fact recently a stapled
peptide entered human trials for the first time.33 Although peptide drugs still have several
obstacles to overcome, they are emerging as a very promising new class of drugs for a vast pool
of untapped drug targets.

1.3 Current Development of BRCA1 Inhibitors
1.3.1 Introduction
The radio- and chemo-sensitive phenotype associated with BRCA1 deficiency points to
inhibition of BRCA1 as a potential therapeutic strategy. However, most of BRCA1’s functions
are mediated by protein-protein interactions (PPIs).9 Historically, achieving PPI inhibition has
been challenging due to the fact that the contact surface of PPIs is often little more than a flat,
large surface void of suitable binding pockets for small molecules.34 However, an increased
interest in PPIs, and the development of intermediate-sized therapeutic agents capable of binding
to large surfaces, has made the inhibition of some PPIs a therapeutically attractive strategy. 35
The complete structure of BRCA1 (see Figure 1.1) has yet to be determined, but the crystal
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Figure 1.1 Potential BRCA1 Therapeutic Targets. BRCA1 with its RING, tandem BRCT,
and overlapping SQ cluster and coiled-coil domains are indicated. Although the BRCT domain
and, to a lesser extent, the RING domain, have been the focus of inhibitor design, others such
as the coiled-coil domain may also be viable targets. The Zn2+binding sites of the RING
domain can be non-specifically inhibited by platinum compounds listed here in order of their
affinity for the domain.48 Extensive exploration of phosphopeptides that bind to the BRCT
domain has resulted in the peptide shown which has a Ki of 40 nM.47a Structural
representations are of the BRCA1 RING and BRCT domains co-crystallized with the RING
domain of BARD1 and a BACH1 phosphopeptide, respectively, and were adapted from PDB
entry codes 1JM749 and 1T29,50 using the PyMOL Molecular Graphics System (Schrödinger,
LLC).
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structures of the N-terminal RING and C-terminal tandem BRCT domains are available to guide
inhibitor development.36

1.3.2 N-terminal RING Domain
The BRCA1 RING domain is composed of a Zn2+ binding region of 8 Cys and His
residues that form two separate Zn2+ binding sites and an adjacent coiled coil region.37 This
domain is known to interact primarily with BARD1, forming a heterodimer that possesses E3
ubiquitin ligase activity. Mutations that result in the loss of BRCA1 ubiquitin ligase activity,
mainly due to the disruption of BARD1 binding,38 render cells sensitive to ionizing radiation.39
Until recently, the BRCA1-BARD1 complex was thought to be constitutive. However, it was
recently demonstrated that when BRCA1-BARD1 binds to p53 in the nucleus, BARD1
dissociates, leading to the export of BRCA1 to the cytoplasm and concomitant sensitization of
cells to DNA damage.40 Therefore, inhibitors of BRCA1 and BARD1 interaction should lead to
radio- and chemo-sensitization. The binding surface between BRCA1 and BARD1 is primarily
composed of a 4-helical bundle, with two helices contributed by each protein. The interface is
quite large (2,200 Å2), and presents a formidable challenge for disruption. There is, however,
some precedent for disruption of helical bundles. For example, the HIV protein gp41 assembles
into a six helical bundle that is disrupted effectively with peptides, including the HIV drug
Fuzeon.41 Interestingly, most cancer-predisposing mutations in the BRCA1 RING domain occur
not in the interface between BRCA1 and BARD1, but in the Zn2+ binding sites of the RING
domain.39b, 42 Platinum based anticancer drugs have previously been shown to preferentially bind
to Zn2+ finger domains, replacing Zn2+ and thereby altering the protein tertiary structure.43
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Recently, it was shown in vitro that platinum agents, shown in Figure 1.1, are able to bind to the
RING domain and inhibit its E3 ubiquitin-ligase activity by ejecting Zn2+.42 The Zn-ligating
residue H117 of BRCA1 was demonstrated to be the primary platinum binding residue.44 Further
work is required to develop specificity for BRCA1 prior to implementing this strategy in living
cells.

1.3.3 C-terminal BRCT Domain
The BRCA1 tandem BRCT domain is a member of a family of BRCT motifs known to bind
phosphorylated proteins involved in DNA repair as well as having other functions.7a,

45

Sometimes these domains exist as a single motif, but often they are found in series, as is the case
with BRCA1. Mutations in this domain are among the most common BRCA1 mutations in
hereditary breast cancer.36a The BRCT domain has potential for inhibitor development due to its
well-defined, relatively small binding cleft known to interact with proteins having pS-X-X-F
motifs.7a,

36a, 36c

Early work using SPOT peptide libraries identified the preferred binding

sequence as phospho-Ser-aromatic β-branched/aromatic-Phe and confirmed that the phospho-Ser
and Phe are the primary requirements for binding.7,

46

The highest affinity peptide from this

screen had an affinity of 162 nM.
Recently, a high-throughput assay based on fluorescence polarization to identify small
molecules that bind to the BRCA1 BRCT domain was developed.47 An initial screen of the NCI
diversity database led to a single hit with an IC50 of 10 μM. Later, a dual fluorescence screen of
75,000 compounds identified 16 inhibitors with the lowest IC50 values in the single digit
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micromolar range. However, some of these compounds have intrinsic fluorescence or act as
fluorescence quenchers, suggesting, as the authors acknowledge, that they may be false positives.
Further optimization of peptide inhibitors by Natarajan and coworkers led to a
tetrapeptide, whose structure is shown in Figure 1.1, with a 40 nM binding affinity.48 Despite the
challenges of drug delivery and cellular stability due to the phosphoserine, one report does exist
showing that a phospopeptide is capable of inhibiting BRCA1 in cellular studies.49 These studies
required very high concentrations of drug (100 µM), and were examined only after very short
time periods of drug exposure. With these limitations combined with the fact that the inhibitory
results were small and far from clinically significant, it is unlikely that continuing to develop
phosphate-based drugs for BRCA1 inhibition will be successful. Thus, therapeutically useful
BRCA1 BRCT inhibitors remain elusive.

1.3.4 PALB2 and SQ Domains
At present, little is known about the BRCA1 structure outside of its two terminal domains. Much
of the internal region of BRCA1 contains evolutionarily conserved sequences, but their function
remains to be fully determined.9 There is, however, the SQ cluster (amino acid residues 1,241–
1,530) with a number of S-Q residues phosphorylated by ATM and ATR.50 These regions
constitute “non-druggable” BRCA1 targets except indirectly by inhibiting these kinases.
Elucidating how the phosphorylation of this internal domain affects the activities of the N- and
C-terminal domains is still an underexplored area, yet is critical to the design of BRCA1-based
therapeutics targeting this region. In addition, the coiled-coil domain (amino acid residues
1,364–1,437) encompassed by the SQ cluster was shown to interact with PALB2 which, in turn,
11

associates with BRCA2.51 Phosphorylation of S-Q residues within the SQ cluster was shown not
to affect PALB2 binding.51b However, the disruption of this interaction by cancer patient-derived
BRCA1 mutations lead to decreased HR and mitomycin C hypersensitivity, 51a making it an
interesting target from a therapeutic standpoint. To block the interaction of BRCA1 and PALB2,
one approach could be the use of hydrocarbon-stapled peptides, which have been shown to
disrupt protein-protein interactions involving helical interfaces.52

1.4 Peptide Selection with Libraries
1.4.1 Peptide Libraries: An Introduction
It is clear that BRCA1 is an important drug target, but it is a difficult target if viewed
through a lens of traditional drug design. This is because its functions are mediated by proteinprotein interactions, but somewhat non-traditional drugs such as peptides are ideally suited for
the challenge. Much progress has been made in the rational design of peptide drugs, yet despite
more advanced algorithms and increased computing power,53 examples of high affinity peptide
drugs from rational design are still rare.54 Therefore, scientists have turned to powerful strategies
for the creation of diverse peptide libraries using “molecular evolution” or “irrational design.”55
In addition to other advantage of peptides as drugs, small molecule screened as potential drugs
are limited by the amount of time it takes to synthesize each unique library member, as well as
the often laborious task of screening each member individually. Unlike small molecules, a wide
variety of peptides can by synthesized relatively easily simply by changing the order of amino
acid addition. Even the smallest peptide libraries far outreach the capacity of high-throughput
screening techniques, and with the ability to easily generate a vast number of peptide members in
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a library, it would be far too daunting a task to screen each library member individually.56
Fortunately peptides have been very amenable to many different types of selections where an
entire library is screened simultaneously against a single target thus dramatically reducing the
time to identify lead sequences.
1.4.2. Immobilized Peptide Libraries (SPOT and OBOC)
Since the 1990s “spot synthesis” of peptides has emerged as a facile way to prepare and
screen a large number of peptides against a desired target.57 Unlike small molecule screening, a
diverse library can easily be synthesized including incorporation of unnatural amino acids, and
due to its immobilization onto solid support the sequence of each peptide is known by its
location.

Screening of a target protein against such a peptide array makes sequencing

unnecessary for identification of lead peptides.

The need to detect bound proteins is one

disadvantage of this technique. Labeling of the protein with a fluorescent tag can lead to
changes in protein properties and solubility, and secondary detection with antibodies can lead to
false positives via non-specific interaction with peptides.58 Additionally, even with advances in
photo lithography a single micro-array contains only 768 members, which limits its power in the
drug discovery process.58
Another method of generating a large peptide library on solid support is known as the
“split and mix” method used in the “one bead one compound” (OBOC) approach developed in
the late 1990s.59 Instead of synthesizing peptides on known locations of a membrane support,
this technique utilizes resin that is split apart before each amino acid addition then recombined
and split again before the next addition. This results in the synthesis of a diverse library with a
decreased number of chemical reactions.60

This technique allows for the incorporation of
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unnatural amino acids, which allows for the creation of a more “drug-like” library. Screening is
often done via on bead binding with detection of bound proteins either by fluorescent probes
fused to the protein or to an antibody.61 Careful selection of resin also allows the application of
flow cytometry for automated counting, which increases the speed of screening.62 Fluorescence
is proportional to the binding affinity, so leads are easily identified, but sequencing is reliant
upon either Edman degradation or MS/MS sequencing, which can be challenging to perform.
However, with the ability to screen 107 to 108 beads/compounds in only a few hours or less, it is
easy to see the power of this technique.

1.4.3 Cellular Display Techniques: Phage and Cell Based Display
Although chemical synthesis of peptides has significantly improved since Emil Fisher’s
initial work in the 1930’s,63 chemical synthesis of peptides is still a highly inefficient process
when compared to the power of ribosomal translation.64 Libraries created through expression of
peptide variants as surface displayed protein fusions have the dual advantages of easy
“synthesis,” and easy sequencing.

Because each peptide library member is generated via

translation, it is inherently linked to a cDNA sequence that can be PCR amplified and sequenced
via routine methods allowing easy identification of library members that bind to the desired
immobilized target. The library size for cell-based libraries is dependent upon transformation
efficiency, and with recent advances can reach up to 1010 members in size,65 but library sizes are
more commonly around 108-109.66
Although cell based displays may provide a means to create larger libraries, they do not
allow for efficient incorporation of unnatural amino acids. Although some labs have the ability
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to incorporate one or two non-natural amino acids via amber and opal codon suppression as well
as other orthogonal genetic incorporations,67 these techniques are limited and not in wide use.
Phage display has become the most widely used of the cell based peptide libraries due in part to
its small particle size in selection, which allows for a smaller host surface to interfere via nonspecific target binding compared to the size of a yeast or bacterial cell.68 The close proximity of
peptides displayed on a phage surface can lead to avidity effects where peptides bind
cooperatively to generate a net high affinity. This is a disadvantage, as it complicates correlation
of phage-displayed and synthesized peptide affinities.

1.4.4 In vitro Display Techniques: mRNA and Ribosome Display
Although the term display was originally used to describe the display of peptides on the surface
of a host, it has come to be synonymous with library technologies that are genetically encoded.
Each display technique shares the advantage that even a single peptide surviving a selection can
have its sequence determined or amplified from its associated code. For bacteria, yeast and
phage display this code or template of the peptide sequence is cDNA; however, as techniques to
work with mRNA have improved, mRNA itself has become a viable purveyor of genotype
directly, such that maintaining cDNA is not necessary to link genotype to phenotype. Using
mRNA to determine peptide sequence requires reverse transcription followed by PCR
amplification, but it has allowed peptide libraries to be created via cell free systems.
Ribosome Display. In Ribosome display the attachment of the mRNA template and translated
peptide is mediated by the ribosome itself (See Figure 1.2). The mRNA is designed such that the
code for the peptide library is followed by a spacer sequence and does not end in a stop codon
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B. Ribosome Display

A. mRNA Display

Figure 1.2 mRNA Display and Ribosome Display. mRNA display and ribosome display are
two methods of generating ribosomaly transcribed peptide libraries in vitro. B) With ribosome
display, the ribosome, mRNA and peptide remain non-covalently attached with a spacer filling
the ribosomal tunnel, so that the library peptide can be “displayed” on the ribosome. A) In
mRNA display, after the ribosome translates the mRNA template into peptide, it stalls at the
double stranded region of the template allowing puromycin (P) to enter into the A site and
form a covalent bond with the peptide forming a genetic link of genotype and phenotype.
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which results in a persistent mRNA-ribosome-peptide complex.

The spacer sequence is

necessary so that the peptide chain can be long enough to exit the ribosomal tunnel and therefore
is “displayed” during selection. The translation reaction is only 5-10 minutes, and after the
reaction is quenched it must be kept at cold temperature (4 °C) throughout the selection.69 One
drawback of this technique stems from the fact that this complex is non-covalent in nature and
therefore selection with ribosome display must be carefully conducted in vitro to preserve the
fragile mRNA-ribosome-peptide complex.
mRNA display. The mRNA-peptide fusion formed during mRNA display overcomes fragile
nature of ribosome display by creating a covalent linkage between the mRNA and peptide thus
eliminating the need for the ribosome to persist in the complex (See Figure 1.2). This is
accomplished with an mRNA lacking a stop codon which is replaced with an extended region
that is complementary to a DNA oligo that acts as a linker for attachment of puromycin.70 After
annealing of the mRNA and DNA, UV crosslinking or splinted ligation forms a covalent
attachment between them. Puromycin is an antibiotic that acts by inhibiting translation. 71 The
slow kinetics of puromycin allow translation to continue at a normal rate without interruption;
however, when the ribosome stalls due to lack of a stop signal at the juncture of double stranded
mRNA/DNA the puromycin has time to enter the A site of the ribosome.72 Once puromycin
enters the A site, the ribosome catalyzes an amide bond between it and the C-terminal end of the
peptide, thus creating a covalent linkage between the mRNA and the single peptide it encoded.
This more stable structure allows a variety of selection conditions with no need to worry about
mRNA and peptide dissociation.
Once this mRNA/peptide fusion has been generated, in reality there are two aptamer
libraries: one of RNA and one of peptide. Because RNAs themselves can bind to a variety of
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targets, the reverse transcription that would be necessary for eventual PCR is conducted prior to
selection so that the RNA is more like a “featureless” negatively charged rod rather than a
molecule with unique secondary structure which could interfere with selection. Because neither
ribosome nor mRNA display are limited by transformation efficiency, libraries up to >10 15 have
been generated.73 In selection, diversity is very important, and a library of this diversity adds
great power to these techniques.74 Additionally being in a cell-free system allows more control
and when conducted as a PURE translation system, UNAAs can easily be incorporated by
substitution rather than cumbersome bio-orthogonal methods.75

1.4.5 Incorporation of Unnatural Amino Acids in Translation
The ability to incorporate UNAAs into proteins or peptides via the translational
machinery offers many beneﬁts.76 For example, the ability to directly incorporate unnatural
amino acids affords direct and simple access to functional groups generally only found in posttranslationally modiﬁed proteins.77 Similarly, the ability to site-speciﬁcally label proteins with
unique functional groups not found in the standard proteinogenic AAs has enabled new means to
control protein function inside cells.78 For peptides, the incorporation of UNAAs can lead to
enhanced stability and permeability, problems that have traditionally hindered the development
of peptides as therapeutics.79 For instance, peptides that contain even a single N-methyl amino
acid can show enhanced bioavailability and protease stability.80 A chief reason to pursue
translational incorporation of UNAAs into peptides is that it in theory expands the chemical
diversity of the already extremely diverse (>1013-member) drug-like peptide libraries using
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techniques like mRNA display.71-72 This ability to create these libraries hinges on the
development of methods to deliver UNAAs into the translation apparatus.
The ﬁrst step for the introduction of UNAAs using in vitro translation is their ligation
onto tRNAs. There are several strategies to achieve formation of non-natural aminoacyl-tRNAs.
The original approach involved chemical attachment of the UNAA onto a dinucleotide followed
by enzymatic ligation onto a truncated tRNA.67a, 81 These chemically charged tRNAs could then
be used with in vitro translation reactions.82 This strategy has now been extended so that instead
of chemically charging individual tRNAs, a whole family of orthogonal aminoacyl-tRNA
synthetase/suppressor tRNA pairs that can be used to incorporate UNAAs site specifically in
vivo.83 An alternative strategy involves charging of a proteinogenic amino acid onto a tRNA,
followed by converting it into an UNAA while attached to the tRNA. For example, reductive
amination can convert a proteinogenic aminoacyl-tRNA into its N-methylated form. This
approach can be used to synthesize peptides containing N-methylated backbones.84 Finally,
Suga, using an RNA catalyst, has developed a means to charge virtually any UNAA ester onto
tRNAs. In their method, an artiﬁcial, ﬂexible ribozyme, called ﬂexizyme, recognizes the 3’ end
of the tRNA in conjunction with benzylic esters of amino acids and charges the amino acid to the
tRNA.85 Four different leaving groups have been developed that can be used to functionalize
essentially any amino acid.86 These leaving groups are recognized by three different flexizymes
hypothetically allowing any amino acid to be mischarged onto a tRNA and therefore
incorporated into translation products.86

This general strategy has been applied for the

incorporation of many UNAAs into peptides.87
Surprisingly, the wild-type aminoacyl-tRNA synthetases are able to charge a wide variety
of unnatural amino acids onto tRNAs.88 This ability suggests that such laborious engineering
19

approaches may not be necessary because incorporation of an UNAA would only require adding
it to an in vitro translation reaction in place of its natural amino acid counterpart. While
conceptually simple, standard cell extracts are highly contaminated with natural AAs, precluding
this strategy. The reconstituted PURE (protein synthesis using recombinant elements) translation
system89 solves this problem because the natural amino acids can be withheld from translation.
Thus the PURE system components can be tailored such that UNAAs are substituted for natural
amino acids.

1.4.6 Unnatural Peptide Library Selections
Directed evolution and library selections have no doubt had significant impact on
biology,90 but there have been many fewer selections conducted with UNAAs present in the
library.

There have however, been several selections performed with UNAAs, that were

successful in producing peptides that bind to various targets with drug-like modifications through
UNAA incorporation.91 One selection is of particular interest because it conducted as two
parallel selections against thrombin, one with only natural amino acids and a second with an
UNAA complement.92 Although in this case, the UNAA peptides selected did not have higher
affinities than the natural peptides selected (both had low nM affinities), they did in fact discover
completely unique binding motifs that no longer bound to the target upon natural amino acid
reversion. UNNA containing peptides such as these are more promising drug candidates from
the outset because of their non-native structures.
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1.5 Characterization of Binding Affinities
1.5.1 What is a Binding Affinity?
The term “binding affinity” is a general term used most commonly to refer to the
equilibrium dissociation constant (Kd). For the simple reaction A + B → AB, a mathematical
description of this constant would be the ratio of the concentration of A and B to the complex
AB at equilibrium (Equation 1, concentrations are denoted in square brackets).
(1)

[ ][ ]
[

]

The Kinetic description of the dissociation constant is a ratio of measured on and off rates of
binding (Equation 2, koff = off-rate, kon = on-rate).
(2)
Thermodynamic analysis of a binding interaction is described in terms of Gibbs free energy (ΔG)
(Equation 3, R = gas constant, T = temperature).
(3)

The Kd of a molecular interaction can be measured through many different types of methods,
many of which provide little description of the molecular details of how the molecules interact.
However, there are other techniques that provide access to Kd through kinetic and
thermodynamic measurements. These measurements provide additional molecular details that
are important for guiding drug design. The strengths and weaknesses of several techniques for
measuring the Kd are reviewed in the following sections.
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1.5.2 Equilibrium Ultrafiltration Binding Assay
Many different methods have been developed to study the binding affinities of molecules.93
Among the simplest of these techniques from a theoretical and application stand point is the
radio-ligand spin assay.94 As the name might imply, this technique requires radiolabeling of the
ligand of interest. In the study of a peptide-protein interaction, this could easily be achieved via
incorporation of 35S-Met into the peptides’ structure. A typical experiment, as shown in Figure
1.3, combines this radio-labeled peptide at constant concentration in multiple samples containing
varying concentration of the protein of interest. After incubation to allow for the peptide to
equilibrate between being free in solution and bound, the sample is placed into a spin filter with a
membrane with specific molecular weight cut off such that the protein will remain in the upper
portion of the spin filter and the unbound peptide will be evenly dispersed in both the sample
remaining in the top portion of the spin filter and the flow through. Scintillation counting of the
two separated solutions allows for mathematical determination of the fraction of radio-labeled
peptide bound to the protein. Equation 4 holds when the volumes above and below the filter are
identical after centrifugation.

From a sigmoidal plot of fraction bound verses protein

concentration, the Kd can be calculated as the inflection point of the graph where 50% of the
protein binding sites are occupied.
(4)

[

]
[

]

[

]
[

]

These assays are technically challenging to perform because slight variations in the volume that
passes through the membrane will skew the results. In addition the data obtained is not as
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Figure 1.3 Equilibrium Ultrafiltration Binding Assay. Various concentrations of
protein are added to a constant concentration of 35S-labeled peptide. After
incubation, the samples are centrifuged in 30,000 MWCO filters until the sample is
divided, half filtered through the membrane, and half remaining in the top. A fraction
bound (FB) can be calculated for each sample and then plotted to achieve a binding
curve.
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precise as many of the other techniques to determine binding affinity. Due to the sensitivity
provided by monitoring binding with scintillation counting, only a small amount of radiolabelled
peptide is need, such that peptides prepared on in vitro translation scale using
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S methionine

incorporation are more than sufficient.
Being the conceptually simplest techniques, as one might expect a radio-ligand spin assay
does not require particularly expensive or sophisticated equipment. The primary hurdle to these
assays is access to radio-labeled ligands. With radio-labeled spin assays reproducibility can be
challenging. Although, this can be mathematically corrected in theory, in actual practice this is
not a highly precise technique.

1.5.3 Isothermal Titration Calorimetry (ITC)
Rudimentary calorimetry qualitatively comparing the “heat of a breeding hen” and the
“head of boiling water” dates back to the 17th century even before the invention of the first
thermometer.95 Since many biological interactions are accompanied by changes in heat, through
the years calorimetry has become an increasingly useful tool.

By the mid-20th century,

calorimeter design had advanced significantly; however, it hasn’t been until the past 20-30 years
that advances have been significant enough to results in affordable, easy to use, stable, and
sensitive enough to result in routine thermodynamic analysis of biological interactions. 95
Modern “microcalorimeters” require as little as 10 nanomoles of sample in a volume of as little
as 200µL.
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Isothermal Titration Calorimetry (ITC) is the modern form of Calorimetry used in
laboratories to measure biological interactions. The instrument is composed of a reference
chamber, containing water or a buffer, and sample chamber as shown in Figure 1.4. Both
chambers are kept at a constant temperature (isothermal), and the sample chamber is fitted with a
long syringe with a paddle-like end that rotates in order to stir the sample. Known quantities of
the ligand are titrated into the sample chamber, and the heat of the interaction between
macromolecule and ligand is indirectly measured after each injection. Because the instrument
maintains a constant temperature, the measurement is the amount of power (microcalories per
second) supplied to the reference or sample chambers in order to maintain a constant
temperature.

In the case of an exothermic reaction more power would be needed for the

reference chamber, and for an endothermic reaction more power would need to be supplied to the
sample chamber to maintain a constant temperature.
Figure 1.5 shows a typical ITC curve of an exothermic reaction. The area under each peak
corresponds indirectly to the amount of heat change (ΔH) occurring as a result of each injection,
with a return to baseline occurring in between each injection. As progressively more ligand is
added, the free protein concentration decreases resulting in progressively smaller peak magnitude
and eventual saturation.

An ideal curve is sigmoidal.

The inflection point gives the

stoichiometry (N) of binding, and the binding constant (K) is most often determined from a
“single site binding constant” model.96 Thus ITC directly gives N, K and ΔH, from which ΔG
and ΔS can be calculated given Equations 5 and 6.

(5)
(6)
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Peptide in Syringe
Protein in Chamber

Sample Chamber

Reference Chamber

Figure 1.4 Setup of an Isothermal Titration Instrumentation. Consisting of two
chambers kept at the same temperature, the reference chamber is filled with buffer
or water. As peptide (or other ligand) is titrated into the protein in the cell, the
current change needed to keep the chambers at a constant concentration is
measured. As more peptide is added and the interaction saturates, a binding
isotherm is obtained, as seen in Figure 1.5.
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Figure 1.5 An Example ITC Isotherm. As aliquots of peptide are added over
time the sample chamber containing protein, the heat released for the binding
events is indirectly measured in µcal/sec. The “heat release” dissipates as binding
sites are exhausted, and a binding curve is observed.
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ITC is the only technique that gives the magnitude of the two thermodynamic values of ΔH
and ΔS. This can be a very powerful tool in guiding drug design because thermodynamic
properties are important for the elucidation of binding mechanisms. Despite this strength, ITC
has its limitations. The biggest of these is governed by the constant c, which is expressed in
equation 7,

(7) c =n[M]TK

where n is the number of binding sites, [M]T is the total macromolecule (usually protein)
concentration), and K is the equilibrium binding constant.18 Sigmoidal curves generally are
observed when c is between 10 and 100.97 A c value that is too low will have a flat curve that
gives little information about binding affinity or stoichiometry. However, a c value that is too
high creates a steep, sigmoidal curve that cannot be accurately interpreted. Given that n and K
are inherent to the binding interaction under study, the only means of manipulating the c value is
to change the concentration of protein in the chamber. Protein solubility and aggregation
typically limit the ability to compensate for low c values with high protein concentrations, while
the sensitivity of ITC limits the ability to use a low protein concentration to compensate for high
c values.

If a fixed protein concentration of 20 µM is assumed in a reaction with 1:1

stoichimetry, ITC is typically limited to measurements of Kds in the range of 2 µM to 200 nM.
ITC is the gold standard of binding affinity measurement because it allows for tag-free
analysis of molecules and study of interactions in thermodynamic detail. This makes it a very
powerful technique because a single experiment can determine all the major thermodynamic
constants of an interaction; however, the high level of calorimeter needed to measure the small
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heats of binding during a titration is quite expensive. After the initial purchase price, the
cleaning and maintenance of these instruments is quite intensive, and can lead to inaccurate data
if not maintained properly. Additionally even the new microcalorimeters require a fairly large
amount of material, especially when compared to fluorescence polarization experiments that can
be adapted to 384 well plates. When combined with an approximately 2 hour experiment time
and the need to run a blank for every sample, it becomes clear to see that this technique is not
adaptable to high-throughput screening.

1.5.4 Fluorescence Polarization (FP)
Also known as Fluorescence Anisotropy, this technique takes advantage of differing tumbling
rates of molecules of varying mass in solution. In 1920 F. Weigert discovered that excitation of
fluorescent dyes with polarized light resulted in emission of polarized light.98 Additionally he
observed that the degree of polarization observed in the emitted light was inversely proportional
to the size of the dye measured. This is to say that smaller molecules that are tumbling faster in
solution “scramble” the light so the emitted light is less polarized, and that larger molecules that
tumble slower maintain more polarity in the emitted spectrum (see Figure 1.6). As complexes
form, naturally the mass increases, which makes FP a suitable technique for studying binding
interactions. In designing an experiment, ideally the fluorophore would be appended to the
smaller of the two molecules under study because this would provide a larger difference in
anisotropy upon binding; however, attaching a large fluorophore to the smaller molecule is more
likely to alter the interaction of the two molecules under study.
measurements are described mathematically in equations 8 and 9,
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Polarization and Anisotropy

Polarized
Light

Depolarized
Light

Polarized
Light

Largely
Polarized
Light

Less
Polarized
Light
Figure 1.6 Fluorescence Polarization. FP analysis takes advantage of the fact that certain
fluorophores emit polarized light when excited with polarized light. When smaller molecules,
like peptides, are excited with polarized light their quick tumbling in solution scrambles the
emitted polarized light. When such a labeled peptide binds to a protein, the rate of tumbling
slows and more polarized light is observed. In a competition assay, a competing peptide
(shown in orange) competes off the fluorescently labeled peptide resulting in the observation of
less polarized (more scrambled) light emitted.
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(8)
(9)

where P is polarization, r is anisotropy, and the intensity of fluorescent readings is represented as
I with subscripts of V and H, where the first letter indicates vertical or horizontal polarization of
the excitation wavelength, and the second indicates the polarization of the emission lens. The G
factor is a corrective value specific to each instrument and fluorophore, and is a measurement of
a sample containing only the fluorescent molecule with horizontally polarized excitation (See
equation 10).

(10)

A typical FP experiment used for binding affinity measurement uses multiple samples at
identical fluorphore concentrations, where each sample has a different known concentration of
the biological molecule it is binding.
Fluorescence polarization, on the other hand, requires less specialized equipment since
fluorescent readings are used in many types of research, and most commonly requires only an
additional purchase of polarizing lenses. Although adaptable to multi-well plate format for highthroughput screening this usually requires more specialized instrumentation. If a multi-well
plate reader is available, FP can use less than 50 uL samples, so its protein requirement can be
fairly minimal. However low affinity interactions are not ideally suited for FP analysis, highly
concentrated samples are needed leading to interference with anisotropy measurements, which
can lead to sample scattering background through either protein aggregation of simply increased
solution viscosity. This can be overcome with IC50 competition experiments, but this is not
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always possible unless another tighter binding molecule is known. If this is the case, a label free
technique such as SPR, ITC or a technique using radio-labels would be more appropriate.

1.5.5 Surface Plasmon Resonance (SPR)
As mentioned previously, SPR is one of the only techniques that continuously measures the
kinetics of a binding event in real time. SPR is an optical technique that relies on activation of
surface plasmons at the interface of a liquid and metal (usually gold). In SPR, the experiment is
conducted with a metal chip where one side of the metal interacts with the optical system, and
the other is a coated surface interacting with the liquid sample.

The coating is usually

carboxylated dextran, but other surfaces can be used to minimize surface effects due to nonspecific interaction of the analyte with the coating. One binding partner is tethered to the dextran
either directly by standard amine, thiol or aldehyde coupling or indirectly through interaction
with an antibody coupled to the dextran surface. Light is reflected at a specific angle and
wavelength from the side of the metal not interacting with the liquid. The refractive index is a
function of mass bound to the surface, and is sensitive to changes in the mass due to binding of
analyte, so the refractive angle of the incident light changes as more mass is bound to the chips
surface. To perform a SPR experiment, as seen in Figure 1.7, an analyte is continuously flowed
over the chip surface, and the changes in refractive index is recorded as a graph of response units
(RU) versus time, where the RU reading is proportional to mass per surface area.99 By repeating
this experiment at various concentrations, the combined data can be fitted to various kinetic
models to calculate the rate-constants which can then be used to calculate the Kd.100 In the case
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Figure 1.7 Surface Plasmon Resonance Experiment with α-GST Antibody. SPR
experiments are based on a mass difference on the surface of a gold sensor chip. As binding
occurs and the mass changes on the surface, the angle of reflected light from the bottom of
the chip changes, and is observed. The most common chips are coated in dextran and
therefore have carboxylic acids available for amine coupling of proteins to the surface. The
protein of interest can be directly coupled to the chip surface, or secondarily via an antibody
as shown here. Once the antibody is couple, the protein of interest immobilized on the
surface via interaction with the antibody. Peptide (or other ligand) is flowed over the chip
surface and the response is measure. On and off rates of binding are determined and used to
find the binding affinity.
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of incredibly fast binding kinetics when the on and off rates cannot be accurately determined,
analysis of the binding at equilibrium at various concentrations is also possible.
Although technically SPR is a “label free” technique, one component of the binding pair,
ideally the smaller of the two, is required to be attached to the surface of a chip. This can be
problematic, because to optimize sensitivity the smaller molecule should be attached to the chip,
and as with attaching a fluorescent tag, alteration of a smaller molecule has the potential to
dramatically change the way it binds. Proteins are much easier to attach to the surface without
altering the interacting interface; however, the additional mass increase from the binding of a
small ligand is often insufficiently sensitive to acquire meaningful data. Because this format is
measuring binding at a liquid/solid interface and not solution phase binding, the experimental
results can complicated by non-specific surface effects that may be observed. In this case trying
different chip surfaces may be required.

In the end, SPR is a great technique for direct

observation of an interaction’s off and on rates, but it can be costly due to the necessary
specialized equipment and maintenance, and is not amenable to a high-throughput format.

1.5.6 Summary of Current Techniques
The techniques discussed above are only some of the many that have been developed to
study the interactions of biomolecules. One of the reasons that so many techniques have been
developed is that there are many advantages and disadvantages to each technique. Each of these
techniques is capable of measuring a Kd, but no single technique can produce all the information
that is necessary to fully understand a binding interaction. A summary of each technique can be
found in Table 1.1.
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Technique
Equilibrium
Ultrafiltration
Binding Assay

Advantages
•
•
•
•
•

Isothermal
Titration
Calorimetry

•
•

•

Fluorescence
Polarization

•
•

Disadvantages

No special equipment needed
Only small quantities of
ligand needed due to
sensitivity of radiolabeling
Label-free technique
Solution phase analysis

•

Allows determination of
thermodynamic constants
Label-free technique
Solution phase analysis

•

Adaptable to high throughput
screening (with appropriate
instrumentation
Solution phase analysis
Can be adapted to small
volumes

•

•

•

•

•

•
•

Monitors on and off rates of
interaction
Label-free technique

•

•

Surface Plasmon
Resonance

•

Not as precise as other
techniques
Must have access to
radiolabeled ligand

Narrow range of ligand
affinity is suitable for this
technique
Expensive
instrumentation and
maintenance
Can be difficult to
analyze low affinity
ligands
Requires addition of
fluorescent tags, which
can interfere with ligand
binding
Special instrumentation
needed for highthroughput analysis
Surface effects from
monitoring reaction on a
chip
Not amenable to high
throughput screening
Expensive
instrumentation and
maintenance

Table 1.1 Summary of Binding Affinity Techniques. Listed in this table are key
advantages and disadvantages of several techniques to determine binding affinities
of a ligand.
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2.1 Introduction
The standard set of amino acids has a wide variety of side chain redundancy. For
example, Glu and Asp, Gln, and Asn, and many of the hydrophobic amino acids (Leu, Ile) have
similar side chains. Therefore substitution of some of these with unnatural amino acids will
expand the diversity of functional groups found in peptides. In the setting of a library selection,
in addition to library size, this expanded group of available functional groups will also increase
the diversity found in the library potentially leading to selection of higher affinity peptides as a
result. Using the PURE translation system, substitution of natural with UNAAs is the simplest
way to generate a large library containing many UNAAs.
The basis of this method is leaving out one or more natural amino acids from the
translation reaction and replacing them with corresponding UNAA analogs that can be charged
by the natural aminoacyl-tRNA synthetases (AARS) onto the tRNA corresponding to the absent
natural amino acids (Figure 2.1). A previous assay to discover unnatural amino acids that are
substrates for AARS found over 92 UNAAs that can be successfully charged by simple
substitution in the PURE translation system.88b In this work we chose eight UNAAs (Figure 2.2)
from this list for possible incorporation into our translation products, including two different
possible tryptophan analogs. These amino acids are all commercially available in their Fmoc
protected forms for solid phase peptide synthesis (SPPS) with the exception of canavanine.
Additionally, the previous study found these UNAAs to be among the most efficiently
incorporated using this substitution method, which makes them good candidates for use together
in translation. After selecting the group of UNAAs to incorporate the next step is to test each of
them individually to assure results similar to previous findings, and if needed optimize each
UNAA individually in translation before combining them.
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W3 o-methyl tryptophan

L3 β-t-butyl alanine

I2 phenylglycine

F26 4-fluoro phenylalanine

R1 L-canavanine

V3 1-amino cyclopentanoic acid

W2 4-fluoro-tryptophan

P1 L-azetidine-2-carboxylic acid

Figure 2.2 UNAA Analogs. These eight UNAAs were chosen to test
for their suitability for use together in translation via substitution with
their natural congeners. The letter in the abbreviation shown in bold
indicates the amino acid for which each analog will be substituted.
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2.2 Testing Individual Unnatural Amino Acids in PURE Translation
Each of the eight UNAAs chosen was added to a translation reaction using one of the
four mRNA test templates listed in Table 2.1. Each translation was conducted on a 50 µL scale
in duplicate with one reaction analyzed by MALDI-TOF-MS to monitor fidelity of translation
and the other sample containing 35S-methionine to monitor yield by scintillation counting. Each
template encodes for a C-terminal FLAG and His6 epitope tag that allows for purification of the
peptides from translation. The C-terminal placement allows only for capture of full length
peptides, so any truncations caused by inefficient incorporation of UNAAs are not observed.
After capture of the peptides with either Ni-NTA or anti-FLAG antibody agarose, the translated
peptides can be eluted and characterized via MALDI. The results of these initial translations are
shown in Figure 2.3a and b. In each case of Figure 2.3 a MALDI analysis of a translation with
all-natural amino reaction with a particular template is shown on the left, and a MALDI analysis
of a translation reaction with an UNAA is shown on the right. Each of these is the initial test of
this particular amino acid. The expected mass, and mass of the primarily observed peak is
shown. The translation test of amino acids L3, F26, R1 show high fidelity and yield; however, for
the other three amino acids some optimization was required.
Troubleshooting yield and ﬁdelity.
When UNAAs are not efficiently incorporated into a peptide during translation, the two
types of errors that occur can generally be classified as either truncations or misincorporations.
Truncation occurs when the UNAA is not an efﬁcient translation substrate, and there are no
competing AAs or AA-tRNAs. Truncations can only be directly visualized by MS if an Nterminal tag is used; however, in these experiments all mRNA templates encoded a C-terminal
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Coding Region

Epitope Tag

MHFSW

DYKDDDDK

MTINR

DYKDDDDK

NLEPQ

DYKDDDDK

MVHM

HHHHHHM

Table 2.1 mRNA Test Templates. List of peptide-encoding sequences used to
analyze analog translation. The full length mRNA sequences can be found in
Ref 74.
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Figure 2.3a Initial MALDI Analysis of UNAA in Translation. The four amino
acid analogues listed on the left were tested for their ability to incorporation into a
translated test peptide via substitution for their corresponding natural amino acid,
and analyzed by MALDI. The all-natural peptides are indicated by white triangle,
and the UNAA peptides are indicated by a black triangle. The yields of the UNAA
reaction compared to the all-natural is indicated. The expected and observed mass
is shown on each MALDI spectrum.
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Figure 2.3b Initial MALDI Analysis of UNAA in Translation Continued. The
four amino acid analogues listed on the left were tested for their ability to
incorporation into a translated test peptide via substitution for their corresponding
natural amino acid, and analyzed by MALDI. The all-natural peptides are indicated
by white triangle, and the UNAA peptides are indicated by a black triangle. The
yields of the UNAA reaction compared to the all-natural is indicated. The expected
and observed mass is shown on each MALDI spectrum.
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tag. A low translation yield with C-terminally tagged peptide is also typically indicative of
premature truncation.
MALDI-TOF MS analysis provides information about the ﬁdelity of the translation and
provides evidence of any misincorporation of other amino acids in place of the desired UNAA. If
the anticipated peptide mass with the UAA is not observed, use of a misincorporation mass table
(Figure 2.4) can be useful to quickly determine the identity of the misincorporated amino acid.
Misincoporations typically are observed when either (1) a near-cognate AA-tRNA is able to
compete effectively at the ribosomal A-site with the UNAA-tRNA containing a cognate codon,
or (2) when residual natural amino acid competes with the unnatural variant for the AARS.
Increasing the concentration of the UAA is typically the ﬁrst strategy we use to improve
ﬁdelity and efﬁciency. Limiting factors to this strategy include the solubility of the UAA, as well
as the possibility that very high concentrations may lead to competition with other AARS (if the
UAA is charged onto tRNA by two different AARS). If increasing the concentration does not
dramatically improve yield, we also typically try to increase the concentration of the appropriate
AARS to enhance the rate of formation of the UAA-tRNA.
If the UAA is a relatively poor substrate for an AARS, even trace amounts of the
contaminating natural AA can be a problem. There are several potential sources of
contamination. A common source is the amino acids themselves. For example, we have found
that Gln is contaminated with Glu and Asn is contaminated with Asp. It is often helpful in these
situations to lower the concentration of the natural amino acid that contains the contaminant
amino acid. Another contaminant source is the E. coli total tRNA which does contain
aminoacylated-tRNA species. These residual AAtRNAs can be removed by deacylation at pH
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75

G
75 G
89 A
105 S
115 P
117 V
119 T
121 C
131 I
131 L
132 N
133 D
146 K
146 Q
147 E
149 M
155 H
165 F
174 R
181 Y
204 W

A
0
14
30
40
42
44
46
56
56
57
58
71
71
72
74
80
90
99
106
129

89 105 115 117 119 121 131 131 132 133 146 146 147 149 155 165 174 181 204
S
P
V
T
C
I
L
N D K Q
E
M H F
R
Y
W
-14 -30 -40 -42 -44 -46 -56 -56 -57 -58 -71 -71 -72 -74 -80 -90 -99 -106 -129
0 -16 -26 -28 -30 -32 -42 -42 -43 -44 -57 -57 -58 -60 -66 -76 -85 -92 -115
16
0 -10 -12 -14 -16 -26 -26 -27 -28 -41 -41 -42 -44 -50 -60 -69 -76 -99
26 10
0
-2 -4 -6 -16 -16 -17 -18 -31 -31 -32 -34 -40 -50 -59 -66 -89
28 12
2
0 -2 -4 -14 -14 -15 -16 -29 -29 -30 -32 -38 -48 -57 -64 -87
30 14
4
2
0 -2 -12 -12 -13 -14 -27 -27 -28 -30 -36 -46 -55 -62 -85
32 16
6
4
2
0 -10 -10 -11 -12 -25 -25 -26 -28 -34 -44 -53 -60 -83
42 26 16 14 12 10 0 0 -1 -2 -15 -15 -16 -18 -24 -34 -43 -50 -73
42 26 16 14 12 10 0 0 -1 -2 -15 -15 -16 -18 -24 -34 -43 -50 -73
43 27 17 15 13 11 1 1 0 -1 -14 -14 -15 -17 -23 -33 -42 -49 -72
44 28 18 16 14 12 2 2 1 0 -13 -13 -14 -16 -22 -32 -41 -48 -71
57 41 31 29 27 25 15 15 14 13 0
0 -1 -3 -9 -19 -28 -35 -58
57 41 31 29 27 25 15 15 14 13 0
0 -1 -3 -9 -19 -28 -35 -58
58 42 32 30 28 26 16 16 15 14 1
1
0 -2 -8 -18 -27 -34 -57
60 44 34 32 30 28 18 18 17 16 3
3
2
0 -6 -16 -25 -32 -55
66 50 40 38 36 34 24 24 23 22 9
9
8
6
0 -10 -19 -26 -49
76 60 50 48 46 44 34 34 33 32 19 19 18 16 10
0 -9 -16 -39
85 69 59 57 55 53 43 43 42 41 28 28 27 25 19
9
0 -7 -30
92 76 66 64 62 60 50 50 49 48 35 35 34 32 26 16
7
0 -23
115 99 89 87 85 83 73 73 72 71 58 58 57 55 49 39 30 23
0

Figure 2.4 Misincorporation Table. The values in the middle of the table
correspond to changes in mass when changing from the amino acid on the top row
to an amino acid on the left-side column.
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8.8 followed by dialysis. Examples of how these strategies can be applied are shown below for
the optimization of P1, V3, and W3
Optimization of P1
Significant enhancement of P1 incorporation was seen upon doubling the analog
concentration from 200 µM to 400 µM (Figure 2.5). Supplementation of proline aminoacyl-tRNA
Synthetase (PRS) was attempted to enhance yield of incorporation, but without success.

Optimization of V3
One UNAA that we have shown can be incorporated with reasonable efﬁciency into
peptides via translation is 1-aminocyclopentanoic acid (V3). To test its incorporation we used the
template encoding MVHMH6M.

Monitoring incorporation by MALDI-TOF in templates

containing a hexahistidine tag can be complicated by glutamine misincorporation. We presume
that this misincorporation arises because the high proportion of His codons and low overall
abundance of tRNAHis leads to depletion of His-tRNAHis during translation.

The

misincorporation results in serial -9 peaks in the MALDI spectrum corresponding to the number
of glutamine misincorporations.
The initial translation experiment showed only a tiny amount of V3 incorporation; the
majority of the peptides contained valine. Because no valine is added to the translation reaction,
the issue with V3 incorporation is the presence of competing valine as a contaminant. Using
deacylated tRNA significantly improved incorporation efficiency, suggesting that Val-tRNAVal
present in the commercial tRNA mix was the culprit. To deacylate the total tRNA, it is treated at
pH 8.8 followed by dialysis to remove any amino acids that had been deacylated.

This

deacylated tRNA led to a dramatic increase in the V3 peptide fidelity (Figure 2.6). Using this
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2 mM

1 mM
LEP1Q
Exp: 1625.67
Obs: 1641.45

LEP1Q
Exp: 1625.67
Obs: 1641.87

Yield: 68 %

Yield: 57 %

Figure 2.5 Titration of P1 Analogue in Translation. In attempt to
increase the fidelity of incorporation of the P1 analogue, its concentration
was increased in the translation reaction. The expected and observed
masses are shown on each MALDI spectrum, and the yield compared to
an all-natural amino acid translation is shown below.
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B

Untreated tRNA + V3
MV3HM
Exp: 1512.56
Obs: 1512.62

MV3HM
Exp: 1512.56
Obs: 1512.45

ΔΔ
Δ
Δ

Yield: 67 %

Yield: 71 %

C

Deacylated tRNA + V3

Δ
Δ
Δ
Δ
Δ

A

Deacylated tRNA
No ValRS

D

Deacylated tRNA
No Val
MVHM
Exp: 1512.56

MVHM
Exp: 1512.56
Obs: 1512.45

Δ

VE

Yield: 93 %

Yield: 83 %

Figure 2.6 V3 Incorporation with Deacylated tRNA. Fidelitiy of 1-aminocylcopentanoic acid (V3) incorporation in place of valine in a template encoding
MVHMH6M. A-B) Comparison of the effect on translation fidelity of V3 incorporation
with untreated and deacylated tRNA. C-D) Translation reactions were also conducted in
the absence of either valine amino-acyl tRNA Synthetase (ValRS) or without valine.
Yields of each reaction compared to an all-natural amino acid translation with all
components are indicated. V3 incorporation is indicated by black arrows and valine
with white arrows.
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deacylated tRNA, we varied the concentration of V3 and showed that 6.4 mM was the best
concentration to use in translation (Figure 2.7). Use of deacylated tRNA did not lower the yield
significantly of any of the peptide templates (Figure 2.8).
Optimization of W3
A translation experiment was conducted along with the F26 and R1 analogs that are also
found in the HSFW template. Knowing that these two analogs incorporate very well and will
likely be used in the final selection experiments W3 is of little use to us if it cannot be
incorporated along with the other analogs. In another experiment, the concentration of W3 was
significantly increased to 1.6 mM based on the available volume in the translation reaction, but
despite this increase the expected mass was not observed at all (Figure 2.9). When a simple
concentration increase failed to produce any W3 incorporation, additional TrpRS was added to
the translation, but this modification was also unsuccessful (Figure 2.10).
Optimization of I2
The primary issue seen with the incorporation of the I2 analog is the significant Ile
incorporation that is seen in addition to the analog. Since no Ile was added to the translation
reaction, it had to be present as a contaminant in one of the reaction components. When
increasing the I2 concentration up to 3.2 mM showed no improvement in out-competing the
natural Ile for incorporation (Figure 2.11). Deacylated tRNA was tested as one means of
contaminant removal (Figure 2.12). The source of Ile contamination does not appear to be from
Ile-tRNAIle because despite using treated tRNA, the misincorporations have the same pattern as
untreated tRNA. Likely the Ile is a contaminant in another reaction component, perhaps a natural
amino acid and is present in sufficient quantities to out compete I2 for the most part. This type of
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6.4 mM

3.2 mM

MV3HM
Exp: 1512.56
Obs: 1512.40

MV3HM
Exp: 1512.56
Obs: 1512.45

Δ
ΔΔ
Δ
Yield: 81 %

ΔΔ
Δ
Δ
Δ
Yield: 94 %

12.8 mM

19.2 mM

MV3HM
Exp: 1512.56
Obs: 1512.45

MV3HM
Exp: 1512.56
Obs: 1512.48

Δ
ΔΔ
Δ

Δ
ΔΔ
Δ
Yield: 68 %

Yield: 60 %

Figure 2.7 Titration of V3 Concentration with Deacylated tRNA. In
attempt to increase fidelity of V3 incorporation, translation reactions were
conducted with tRNA as well as increasing V3 concentrations as indicated.
The expected and observed masses are indicated, as well as the reaction
yields. V3 incorporation is indicated by the black triangles and valine with
white.
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Percent Yield of Untreated
tRNA (%)

140
120
100
80
60
40
20
0

MVHM
MVHM

TINR
TINR

HFSW
HWFW

LEPQ
LEPQ

mRNA Template

Figure 2.8 Effect of Deacylated tRNA on Peptide Yield. In order to asses a
general effect of deacylated tRNA on peptide yield, translations were conducted
with the test peptides. The graph shows the percent yield compared to
translations with untreated tRNA.
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1.6 mM
HF26SW 3
Exp: 1761.68
Obs: 1721.87

Figure 2.9 Increase in Concentration to Improve W3 Fidelity. A 50 µL
translation with an increased concentration of W3 in attempt to increase its
incorporation. The peptide product was not observed.

12 µM TrpRS
HF26SW 3
Exp: 1761.68
Obs: 1667.95

Figure 2.10 Increase in to Improve W3 Fidelity. A 50 µL translation with an
increased concentration of Tryptophan amino-acyl synthetase (TrpRS) in final
attempt to observe its incorporation. The peptide product was unable to be
identified.
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3.5 mM

Δ

TI2NR1
Exp: 1676.84

Figure 2.11 Incorporation of Analogue I2 with a High Amino Acid
Concentration. Despite the high concentration of the I2 analogue in the
translation reaction, no peak with the expected mass was observed. However
a peak corresponding to the all-natural peptide was seen and is marked with
a triangle.
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TINR

Un-treated
tRNA

TMNR

TI2NR

TMNR

1 hour
Deacylated

TINR

TI2NR

TMNR

2 hour
Deacylated

TINR
TI2NR

Figure 2.12 Analogue I2 Deacylation Tests. To test the effect of tRNA deaclyation on the
fideltity of I2 incorporation, 50 µL translations were conducted with untreated, deacylated
tRNA that had been treated with base for either 1 hour or 2 hours. Misincorporations are
marked with an underline.
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contaminant can be more difficult to remove, and it was decided not to include I2 in the UNAA
mix for selection.

2.3 Combination of UNAAs in PURE Translation
Efﬁcient incorporation of the UAA into a single template does not guarantee that it will
be efﬁciently incorporated into peptides when combined with other analogs. Before progressing
to translation with the library templates, it was necessary to test all of the UNAAs with each of
the templates. One reaction contained all the FLAG templates, and the other the single His6
template, but both had all 6 desired UNAAs. The results from these tests (Figure 2.13) showed
expected fidelity and yield based upon prior testing of individual amino acids, so testing with
library templates was pursued. The final concentration of amino acids used in translation can be
found in Table 2.2.
2.4 Testing UNAAs with Library Templates
After successful translation of the six final peptides in the same translation
reaction a final assessment of the effect of UNAA incorporation on peptide yield was assessed
using the actual template to be used in the selection (Figure 2.13). It is not possible to observe
the peptides encoded by the randomized library because in theory they should each have
different sequences. Thus fidelity is assumed to be the same as that observed in previous
experiments. When the translation reactions with library mRNA templates were supplemented
reaction (Figure 2.14).
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HF26SW2

A

Exp: 1748.92
Obs: 1750.22

L3EP1Q

Exp: 1639.82

TINR1

Exp: 1658.78
Obs: 1660.16

MVHM

MV3HM

Exp: 1510.70
Obs: 1511.79

B

Figure 2.13 Translation with All Six UNAAs. For a final test of translation fidelity
with all six UNAAs, two 50 µL translations were conducted with all six UNAAs
present. A) The translation reaction containing the three FLAG-tagged templates.
Peptide products containing UNAAs are marked with arrows, and the expected and
observed masses are written. B) Another translation was conducted with the MVHM
His6-tagged template. V3 incorporation is marked with black arrows, and valine
incorporation with gray arrows.
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Table 2.2 Final Concentration of Unnatural Amino Acids and PRS. These are
the only deviations to the in vitro translation reaction conditions described by Ma
and Hartman (Ref 101).

Amino Acid/Synthetase

Symbol

4-fluoro-DL-tryptophan
L-canavanine
L-azetidine-2-carboxylic acid
4-fluoro-phenylalanine
β-t-butyl-L-alanine
1-aminocyclopentane-1-carboxylic acid
Prolyl aminoacyl-tRNA Synthetase

Wa
Ra
Pa
Fa
La
Va
PRS
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Concentration in
Translation Reaction
0.8 mM
0.4 mM
1.0 mM
1.6 mM
6.6 mM
6.4 mM
0.31 µM

Translation Yield %

Library Translation
100
90
80
70
60
50
40
30
20
10
0

All Natural

Unnatural Mix

Figure 2.14 Yield of All 6 UNAAs with Library Templates. 250 µL translations
were conducted with the CX12 library template that will be used for selection to
compare the yield of incorporation of the six UNAAs to an all-natural amino acid
translation.
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2.5 Discussion
In search of a bioavailable and high affinity peptide, unnatural amino acids were
substituted for some of the 20 natural amino acids in translation. Based on our previous work
describing amino acid analogs that can be incorporated by substitution in ribosomal
translation,101 a group of six unnatural amino acids were optimized for use together with the
other 14 natural amino acids in translation. Translational efficiency was measured by
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S-Met

incorporation, and translational fidelity was determined by MALDI-TOF analysis. Amino acid
analogs W2, F26, R1 and L3 were incorporated with high efficiency in place of their natural
congeners; however, additional modifications were required for incorporation of the W 3, I2 and
V3 and P1 analogs. Attempts to increase amino acid concentration and add the corresponding
AARS or use deacylated tRNA were unsuccessful in achieving high fidelity incorporation of the
W3 and I2 analogs. However, treatment of total E. coli tRNA with mildly basic conditions to
remove residual Val-tRNAVal along with addition of higher V3 concentrations was sufficient to
remove the majority of valine contamination in translated peptides allowing successful
incorporation of the V3 analog.102

Attempts to improve the yield of P1 by increasing its

concentration in the reaction were successful; however, improving yield by supplementing the
translation reaction with additional proline aminoacyl-tRNA Synthetase (PRS) was unsuccessful.
Because W3 was unable to be successfully optimized and was therefore replaced with the
efficiently incorporated W2 analog, while I2 was dropped altogether.

59

2.6 Experimental
General Reagents
Putrescine, spermidine, potassium chloride (KCl), ammonium chloride, magnesium acetate
tetrahydrate (Mg(OAc)2), calcium chloride (CaCl2), potassium hydroxide (KOH), nucleoside 5´diphosphate kinase from bovine liver, D,L-dithiothreitol (DTT), myokinase from rabbit muscle,
adenosine 5´-triphosphate disodium salt, guanosine 5´-triphosphate sodium salt hydrate, ANTIFLAG M2-Agarose from mouse, triﬂuoroacetic acid spectrophotometric grade and a-cyano-4hydroxy-cinnamic acid were purchased from Sigma–Aldrich. Potassium acetate (KOAc), water
Optima LC/MS grade and acetonitrile Optima LC/MS grade were purchased from Fisher.
Potassium phosphate dibasic (K2HPO4) was purchased from Caledon. Creatine kinase and
Escherichia coli total tRNA were purchased from Roche Applied Science. Creatine phosphate
potassium salt was purchased from Merck/EMD. (6R,S)-5,10-formyl-5,6,7,8-tetrahydrofolic acid
(methyl tertahydrofolate) was purchased from Schircks Laboratory. All natural L-amino acids
were purchased from Fluka in their highest purity form. 35S-Met (Speciﬁc Activity: >1000 Ci
(37.0 TBq)/mmol) was purchased from Perkin-Elmer. 1-Aminocyclopentanoic acid was
purchased from Chem-Impex International. Zip Tip C-18 columns were purchased from
Millipore. Ni-NTA agarose was purchased from Qiagen.
Amino acids.

Unnatural amino acid sources: Wa: 4-fluoro-DL-tryptophan (Sigma), Ra: L-

canavanine (Sigma), Pa: L-azetidine-2-carboxylic acid (ChemImpex), Fa: 4-fluoro-Lphenylalanine

(ChemImpex),

La:

beta-t-butyl-L-alanine

(ChemImpex),

and

V a:

1-

aminocyclopentane-1-carboxylic acid (ChemImpex). All natural amino acids were purchased
from Fluka in their highest purity form.

All amino acids were dissolved in H2O at a

concentration of 10 mM or at maximal solubility and KOH was added to a final pH of 7.0-7.5
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followed by sterile filtration. Isotopically labeled
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S-Met (1000 Ci/mmol) was from Perkin

Elmer.
Translation Factors, Enzymes and Ribosomes. All purified enzymes were stored at -80 °C in
enzyme storage buffer (50mM HEPES-KOH pH 7.6, 100mM KCl, 10mM MgCl2, 7mM BME,
30% glycerol) with the exception of MetRS which was kept in enzyme storage buffer with 50%
glycerol at -20 °C. Ribosomes were prepared as described.103
Instrumentation
MALDI-MS experiments were performed on a Micromass MALDI-R MALDI-TOF Mass
Spectrometer.
Preparation of mRNAs for Translation
mRNAs were prepared using T7 in vitro transcription according to described protocols.88a The
DNA templates were created using two different methods. The ﬁrst method involved ligating
synthetic DNA duplexes with sticky ends into a pET12b vector, followed by PCR using the
primers complementary to the vector encoded T7 promoter and terminator. Alternatively, a
single synthetic oligonucleotide complementary to the T7 promoter, Epsilon enhancer, ShineDalgarno, and coding region was used as a template for runoff T7-mediated in vitro
transcription.
Preparation of Amino Acid Stocks for Translation
Each UAA was dissolved to a ﬁnal concentration of 10 mM, the pH was adjusted to 7.0–7.5 with
1 M KOH, ﬁltered through 0.22 µm syringe ﬁlter, and stored at -20 °C
In vitro Translation
Each translation reaction was carried out as previously described.88a Each reaction (50 µL)
contained putresciene (8 mM), spermidine (1 mM), potassium phosphate (5 mM), potassium
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chloride (95 mM), ammonium chloride (5 mM), magnesium acetate (5 mM), calcium chloride
(0.5 mM), dithiothreitol (1 mM), inorganic pyrophosphatase (1 µg/mL), creatine kinase (4
µg/mL), nucleotide diphosphate kinase (1.1 µg/mL), (6R,S)-5,10-formyl-5,6,7,8-tetrahydrofolic
acid (30 lM), myokinase (3 µg/mL), creatine phosphate (20 mM), ATP (2 mM), GTP (2 mM), E.
coli total tRNA (2.4 mg/mL), IF-1 (1 µg), IF-2 (2 µg), IF-3 (0.75 µg), EF-G (1 µg), EF-TS (1
µg), EF-Tu (2.24 µg), RF-1 (0.5 µg), RR-F (0.5 µg), RF-3 (0.5 µg), ribosomes (0.5 µM), 35SMethionine (0.4 µM), methionine (10 µM), 19 AA (200 µM), MetRS (0.1 µM), LeuRS (0.3
µM), GluRS (0.6 µM), ProRS (0.2 µM), GlnRS (1.0 µM), HisRS (1.0 µM), PheRS A294G (2.5
µM), TrpRS (1.5 µM), SerRS (0.2 µM), IleRS, (0.2 µM) ThrRS (0.4 µM), AsnRS (0.6 µM),
AspRS (0.6 µM), TyrRS (0.5 µM), LysRS (0.5 µM), ArgRS (0.4 µM), ValRS (0.2 µM), AlaRS
(0.2 µM), CysRS (0.5 µM), GlyRS (0.6 µM), MTF (0.2 µM) and mRNA template (1.14 µM).
The translations were initiated by addition of the appropriate mRNAs. For initial testing
of UAAs, 19 natural amino acids were included (200 µM each) with only one UAA. After
incubation of the translation for 1 h at 37 °C, the reactions were quenched with 150 µL PBS (if
using FLAG tag) or 150 µL TBS with 5 mM BME (if using His-tag). Forty microliters of NiNTA resin or 10 µL ANTI-FLAG M2 agarose was added to a 500 µL centrifugal ﬁlter along
with the quenched translation reaction, and the mixture was tumbled at room temperature. After
1 h, the resin was washed three times with 500 µL TBS and eluted with 1% triﬂuoroacetic acid
(TFA) (50 µL). For reactions labeled with 35S-Met, the yield was determined by scintillation
counting of half (25 µL) of the elution. To examine the ﬁdelity of the UAA incorporation, the
non-radiolabeled reactions were puriﬁed and concentrated by Zip-Tip C18 chromatography. The
Zip-tips were ﬁrst wetted with acetonitrile, followed by 1:1 acetonitrile, then with 0.1% TFA.
Then the peptide was loaded onto the tip by pipetting up and down 15 times in the peptide
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solution. The tip was washed three times with 0.1% TFA, and then eluted with 5 µL CHCA
matrix (a-cyano-4-hydroxycinnamic acid in 1:1 MeCN:0.1% TFA). An aliquot (1 µL) of the
resulting suspension was spotted on a MALDI plate and analyzed.
tRNA Deacylation
E. coli total tRNA (100 mg/mL) dissolved in 1 M Tris–HCl (pH 8.8) and was incubated at 37 °C
for 2 h, followed by dialysis overnight at 37 °C against 50 mM Tris–HCl (pH 8.8). The tRNA
was precipitated by ﬁrst adding 0.1 volume of a solution of KOAc (3.0 M, pH 5.5) and 3
volumes of ethanol. The pellet was washed twice with 70% ethanol, and allowed to air-dry at
room temperature. The tRNA was resuspended in ddH2O and the concentration was adjusted to
100 mg/mL (1.6A260/µL). The tRNA was aliquoted and stored at -80 °C.

2.7 Summary
Of the eight UNAA tested, six were found to work well together in translation. The F 26,
W2, L3 and R1 analogs were successful in initial testing. P1 and V3 required increased amino acid
concentration to be successfully incorporated, with V3 also requiring the use of deacylated
tRNA. W2 and I2 on the other hand were not able to be incorporated with high fidelity despite
modifications to the translation reactions.

Fidelity of these UNAA incorporations was

maintained when they were combined, and overall yield was 30% of the all-natural yield with
library templates.
Future Directions. These 6 UNAAs will be used together in translation for mRNA display
selection against the (BRCT)2 domain of BRCA1.
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CHAPTER 3. STRENGTH IN NUMBERS: mRNA-DISPLAY LIBRARY SELECTION
AGAINST BRCA1-(BRCT)2

Contributions:
Zhong Ma and ERW performed experiments leading to the optimization of selection as well as
the actual selection experiments.
Melissa B. Huie, was responsible for cloning of GST-(BRCT)2 fusion protein.
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3.1 Introduction
Perhaps the best studied (BRCT)2 domain protein is BRCA1. This protein is involved in
various DNA repair pathways, and its C-terminal tandem BRCT domain36c, 45, 104 is known to
bind selectively to phosphoprotein partners. The well-defined and relatively small binding cleft
of the (BRCT)2 domain, and the fact that the many mutations that occur in this domain lead to
chemotherapeutic and radiation sensitization by disruption of DNA repair, make it a promising
therapeutic target.105

In addition, BRCA1 is involved in at least three different protein

complexes mediated by the (BRCT)2 domain.106 Its involvement in each of these dynamic
complexes is dependent on the cell cycle and on the extent of DNA damage. Inhibitors of this
domain would therefore allow dosable and temporal control of BRCA1 complex formation.
High throughput in vitro small molecule screens have uncovered molecules that bind to
BRCA1 in the 5-10 micromolar range,47a yet their activity in cell culture and target selectivity
have not been established. Currently, the best binders of this domain are phosphoserinecontaining peptides.

Several phosphopeptide library screens as well as comparisons of

endogenous protein binders have determined that the preferred binding sequence for this domain
is phosphoserine (pS)-X-X-F.104, 107 Libraries lacking phosphoserine were shown not to bind.104,
107

Natarajan and coworkers have used rational design to optimize binding based on pS-X-X-F

and have recently found a pS-containing modified tetrapeptide with a Kd of 40 nM.108 A recent
report showed this phosphopeptide can abrogate BRCA1 function, but the effect was minimal
and required high concentrations of peptide making it far from a useful therapeutic or tool.49
Yet, attempts to replace phosphoserine with phosphomimetic groups have led to dramatically
weakened binding affinity.48b, 109
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We reasoned that by using a peptide library of sufficient size and functional diversity, a nonpS containing peptide could be found that binds to the (BRCT)2 domain of BRCA1. There are
many methodologies that have been developed for creation of peptide libraries, but mRNA
display110 provides advantages over other techniques because of the potential for incorporation of
non-canonical amino acids111 as well as the ability to prepare libraries with up to 1013 unique
peptides,110b, 111c 3-6 orders of magnitude more diverse than is possible with on-bead synthesis or
phage display. With this increased diversity may come an improved chance of finding higher
affinity peptides.112
In choosing these UNAAs we have purposefully left out phosphoserine which has been
regarded in the literature as a requirement for binding to the BRCA1-(BRCT)2 domain.
Additionally, attempts to incorporate phosphomimetic analogs into BRCA1-(BRCT)2 binding
peptides have not found great success and in many cases nearly abolish peptide binding. We
hope to uncover an alternative means of binding to this domain that is not reliant upon
phosphoserine. Such a peptide would be more amenable for use as a drug owing to increased
stability and cell permeability.

3.2 Selection Preparation and Optimization
Library Design. The DNA library contained a 12 amino acid random region encoding the
peptide sequence MCX12GSGSLaGH6RaLa, with the random, X, amino acids designated by the
codon NNB (B = G, T or C) (Figure 3.1A). Usage of this codon vs. the standard NNS/NNK
served to decrease the number of stop codons present in the random region (1/48 vs. 1/32 for
NNS/K) while also increasing the likelihood of a second Cys (2/48 vs. 1/32) such that
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NNB = semi-random codon
Where N = (A, G, C, or T)
and B = (G, C, or T)

A
mRNA
peptide

AUGUGCNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBNNBGGCUCCGGUAGCUUAGGCCACCAUCACCAUCACCAU
Met Cys X X
X X X X X X X X X X Gly Ser Gly Ser Leu Gly His His His His His His

C
B

SH

HS

Figure 3.1 Library Design. Peptide library design for selection against the
(BRCT)2 domain of BRCA1. A) the mRNA sequence encoding the peptide
library including an N-terminal fix cysteine (red) followed by a 12 amino acid
random region (black and gray), a Gly-Ser linker (green) and a His6 tag (blue).
B) A codon table displaying remaining available codons with use of the NNB
codon where B = G, C, or T, thus eliminating two of three potential stop codons
and enriching the presence of cysteine in the library. C) Cyclization of library
members with an additional cysteine in the random region will be accomplished
via a cyclization reaction with dibromoxylene.

1
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approximately 40% of the initial library should contain at least one additional Cys (Figure 3.1B).
The addition of a second cysteine was desired to enable cyclization with α-α’-dibromo-m-xylene
(Figure 3.1C).111c, 113 Cyclization is beneficial because it can enhance affinity, cell permeability,
and stability.114
Expression of GST-(BRCT)2 fusion (01-85)
The BRCA1 (BRCT)2 had previously been cloned into pGEXx4T-1 vector for expression
as an N-terminal glutathione S-transferase (GST) fusion. Using a BL21 Codon Plus (DE3) RIL
strain, the protein was expressed via ZYM-5052 auto induction overnight at 18 °C.115 The
protein was purified with tandem Ni-NTA agarose (Qiagen) and Glutatione agarose (Thermo)
affinity resin and gave 3 mg/L culture. Resultant protein was > 95 % pure by SDS-PAGE
analysis (See Figure 3.2), and was stored in enzyme storage buffer at -80 until needed.
Capture and Release of GST-(BRCT)2 with Magnetic GSH Beads In order to perform the
capture and elution of the library it is necessary to optimize the binding and release of the protein
from its immobilized support. An initial test of bead binding and elution (Figure 3.3A) showed
an acceptable level of protein fusion binding to the bead; however a significant amount of
protein remained on the beads after four rounds of exposure to 120 µL elution buffer (125 mM
Tris pH 8.25, 50 mM GSH, 500 mM NaCl, 1 % Triton X-100) for 10 minutes each. To improve
the elution, we tested four buffers noted for their enhanced stringency: 1) 250 mM Tris pH 9.0,
100 mM GSH, 500 mM NaCl, 1 % Triton X-100, 2) 125 mM Tris pH 7.5, 500 mM NaCl, 0.1 %
SDS, 5 mM DTT, 3) 100 mM Glycine pH 2.85, 500 mM NaCl, 0.1 % Triton X-100, 4) Boiling
in TBS (50 mM Tris pH 8.0, 300 mM NaCl) for 5 minutes.
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Figure 3.2. SDS-PAGE Analysis of Purified Fusion Proteins. Analysis
of purified BRCT fusions by SDS-PAGE and staining with Coomassie Blue
shows proteins estimated to be >95% pure. The expected mass of GSTBRCT is 51.3 kDa, and TR-BRCT is 42.9 kDa.
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Marker
GST Input
GST bound to beads
GST-BRCT Input
Flow Through
Wash
Elution 1
Elution 2
Elution 3
Remaining Beads

A

50 kDa
37 kDa

Input

B

Beads 1
Beads 2
Beads 3
Beads 4
Flow Through

25 kDa
20 kDa

Figure 3.3 Elution of GST-(BRCT)2 Fusion from Glutathione Beads. Only
peptides bound to immobilized GST-(BRCT)2 that is successfully eluted will be
carried on in the next round of selection so it is important that as much of the fusion
be eluted as possible after selection. A) An initial test of the protein fusion binding
an elution shows significant protein fusion remaining on the beads (see lane on far
right). B) Four elution buffers (see text for details) were tested to find a more
stringent buffer capable of complete elution of the protein fusion.
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After one round of elution with 200 µL for 10 minutes, buffers 1 and 2 left no detectable protein
bound to the bead (Figure 3.3B). Buffer 1 was chosen for use in the library selection.

3.3 mRNA Display Library Selection Against BRCA1-(BRCT)2
The general scheme of the selection process is shown in Figure 3.4. The mRNA peptide fusion
library was prepared in the standard way.111c, 116 Briefly, mRNA was photocrosslinked onto a
puromycin-DNA linker. After translation in the presence of unnatural amino acids, a library of
mRNAs covalently linked to the peptides they encoded was formed. The mRNA-peptide fusions
were purified via Oligo-dT cellulose and cyclized on the resin, followed by reverse transcription
and Ni-NTA purification. The translation was performed on a large (10 mL) scale for round 1
leading to the creation of 1.3 x 1013 mRNA peptide fusions, each theoretically unique. The
(BRCT)2 domain of BRCA1 was prepared as N-terminal GST-fusion. This fusion protein was
immobilized onto glutathione (GSH) magnetic beads, and the mRNA peptide fusions were
allowed to bind. Bound mRNA-peptide fusions were sequestered using a magnet, followed by
several washes. Elution of the GST fusion from the beads was achieved via competition with
excess GSH. PCR of the mRNA-peptide fusions amplified the recovered fusions. The resulting
DNAs were in vitro transcribed and the process repeated iteratively. The percentage of the
eluted
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S-Met-containing mRNA-peptide fusions vs. the total input was calculated in each

round. In the first six rounds, very little enrichment was seen, but after the initial spike in round
seven, the beginning of a plateau was seen in round 8 (Figure 3.5).
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Figure 3.4 In vitro Selection Scheme. The DNA library encodes a twelve amino acids
random region with an N-terminal cysteine. After peptide fusion formation, peptides
with a second cysteine are cyclized with dibromoxylene. Purified mRNA-peptide
fusions undergo reverse transcription and his-tagged purification before being selected
for binding to the GST-(BRCT)2 fusion immobilized on magnetic resin. Unbound
peptides are washed away and bound peptides are eluted, PCR amplified, and carried
through another round of selection. Structural representation of the BRCA1 (BRCT) 2
domain was adapted from PDB entry code 1T29 using the PyMOL molecular graphics
system (Schrodinger, LLC).
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Figure 3.5 Selection Progress. The percentage of 35S-Met labeled peptide eluted
with GSH relative to the total 35S-Met input from each round of selection was
calculated and is shown for each of eight rounds.
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3.4 Sequencing
After the plateau beginning in the eighth round, the cDNAs corresponding to the selected
peptides were sequenced following cloning. As shown in Figure 3.6, of the 85 sequences found,
7 sequences appeared more than once, and these duplicate sequences comprised more than 80 %
of the total sequencing hits. Alignment of the top seven sequences is shown in Figure 3.7.

3.5 Discussion
Unnatural amino acids appeared many times in the random region of the selected
sequences, but the variety of different amino acids was limited to primarily F26 and R1. Analogs
L3 and P1 were present in families 8.3/8.4 and 8.7 respectively, while V3 and W2 were limited to
single appearances in the “other” sequences. The most notable motif is the recurring D/E-X-XFa sequence that is found in 80 of the 85 sequences. This motif is remarkably similar to the pSX-X-F motif known to be found in all known BRCA1 (BRCT)2-domain binding proteins,106, 117
where the Phe is replaced with 4-fluoro-Phe and the pSer is replaced with either aspartic or
glutamic acid, both being known, but weak pS-mimetics.118 These results were somewhat
surprising, because prior attempts to mutate pS to E led to abrogated BRCA1 binding.109
Previously oriented SPOT library screens have shown that peptides containing β-branched and
aromatic AAs in the X-X positions are preferred.107 This preference is also mirrored in many of
our sequences.

3.6 Experimental
Protein Expression. The plasmid construct containing the BRCA1 (BRCT)2 domain (amino
acids 1646-1859)119 was digested with restriction enzymes NdeI and XhoI. PCR amplification
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Figure 3.6 Selection Sequencing Results. After round eight, cDNA from the
library pool was cloned and sequenced giving the 85 sequences shown, and
similar sequences were arranged into 7 families. Unnatural amino acids are
designed in red.
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MCNDFIFRRSTFRA
8.1
MCSDFIFSRRTYTF
8.2
MCNDFTFDKNLNHH
8.3
MCHNDFAFAKTSLY
8.4
8.5 MCYDFDTTNDHTFI
MCTIDFDEYRFRKT
8.6
MCDFQFRKPSTTIY
8.7
Consensus Seq
DXXF
D F I F
Prior Selection Studies
pSXXF
pS X X F
Selection
Prior studies5

Branched

Aromatic

Figure 3.7 Family Sequence Alignment. The top seven families are aligned
with respect to the D/E-X-X-F motif found in each family (emphasized with
a gray rectangle). Un-nautral amino acids are indicated in red.
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with primers BRCT FWD (5’-CGGGATCCGTCAACAAAAGAATGTCCATGGTGGTGTC3’) and REV (5’-CCGCTCGAGTCAGTGGTGGTGGTGGTGGTGGGGGATCTGGGGTATC3’) were used to amplify the insert creating a BamHI restriction site at the N-terminus and adding
a hexahistidine tag to the C-terminus. The insert was then ligated into a pGEX-4T-1 vector to
form a C-terminal Glutathione S-Transferase (GST) fusion which was then verified by
sequencing. After transforming into E. coli strain BL21(DE3)-RIL cells, protein expression was
induced with auto-inducing ZYM-5052 media120 with overnight incubation at 18 °C.
Additionally a modified pET32a vector previously described121 was used to prepare an Nterminal thioredoxin fusion with C-terminal His-tag (TR-BRCT). The pGEX-4T-1 vector was
digested with BamHI and XhoI and ligated into the modified pET32a. After transformation into
BL21 (DE3) strain of E. coli, cells were expressed using auto-inducing media overnight at
18 °C.115 The recombinant protein was purified via tandem affinity purification, first with
binding to Ni-NTA agarose (QIAGEN) while tumbling at 4 °C for 60 minutes. After washing
twice (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 5mM BME), six elutions (1.5 ml
each of 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 5 mM BME) were combined an
dialyzed overnight into 1X PBS. After dialysis, protein was combined with glutatione-agarose
resin (Thermo) while tumbling for 1.5 hours at 4 °C. The resin was washed twice with 1X PBS
and the GST-fusion protein was eluted with 6 x 1 mL fractions (50 mM Tris pH 8.0, 10 mM
glutathione). The resulting yield was 3 mg/L and fusion proteins were >95% pure as estimated
by SDS–PAGE analysis. Protein was stored at -80 °C after dialysis in enzyme storage buffer (50
mM HEPES-KOH pH 7.6. 100 mM KCl, 10 mM MgCl2, 7 mM BME, 30 % glycerol).
Test of GST-(BRCT)2 Immobilization onto Magnetic Beads. Purified GST-(BRCT)2 fusion
protein was diluted 1:5 with binding buffer (50 mM Tris-HCl pH 7.8, 150 mM NaCl, 4 mM
77

MgCl2, 0.25 % Triton X-100, 0.1 mg/ml BSA) and incubated with glutathione magnetic beads
(Thermo) with tumbling for 1 hour at 4 °C. Any unbound protein was taken as the flow through
and beads were washed with twice with binding buffer. Bound protein was eluted with elution
buffer indicated, and fractions of each step were analysed with a 10 % SDS-PAGE gel.
Preparation of mRNA Fusions. The in vitro selection protocol has previously been outlined in
detail116 and is described here in brief. The sequence of the cDNA encoding the mRNA display
library was: 5’-CTAGCTACCTATAGCCGGTGGTGATGGTGATGGTGGCCTAAGCTACCG
GAGCCVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNVNNGCACATTTAGCTGT
CCTCCTTACTAAAGTTAACCCTATAGTGAGTCGTATTA-3’.

The library was ordered

from the HHMI/Keck synthesis facility and was purified by Urea-PAGE. Following PCR
amplification of library templates, sequences were verified with TOPO cloning and sequencing.
An in vitro transcription reaction was followed by Urea-PAGE purification and electroelution to
obtain purified mRNAs to be used for selection. The library mRNA was photochemically
crosslinked to a puromycin linker after annealing followed by exposure to UV irradiation, and
was then used in translation to produce peptide-mRNA fusions. A 10 mL scale translation was
used to generate peptides for the first round of selection. After translation, fusion formation was
maximized through the addition of KCl/Mg(OAc)2 as described.122 The mRNA peptide fusions
were bound to Oligo(dT) resin via the poly-A sequence contained in the puromycin linker.
Peptides were cyclized on the resin using dibromoxylene, and eluted with water. The cyclization
reaction was conducted as described.111c This was followed by reverse transcription of the
mRNA with a primer of the sequence 5’-TTTTTTTTTTTTTTT CTAGCTACCTATAGCCGGT
GGTGATGGTGATGGTGGCCTAAGC-3’, and Ni-NTA purification of the full-length peptide
fusions containing a C-terminal hexahistidine tag. The library was then dialyzed into selection
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buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 4 mM MgCl2, 0.25% Triton X-100) and used in
the first round of selection. The yield of peptide fusions after all purification steps was 22 pmol,
equivalent to 1.3 x 1013 peptides.
Selection. Prior to the selection, beads containing GST and GST-BRCT were prepared. GST
beads: 200 µL of magnetic glutathione beads (Pierce) were washed three times with 1 mL GSH
beads wash buffer (125 mM Tris-HCl pH 8, 150 mM NaCl). 1 mL of 10 µM GST in GSH beads
wash buffer was added to the beads and tumbled for 1 hour at 4°C. The supernatant was then
discarded and the beads were washed 2x with 1 mL GSH beads wash buffer and 1 x 1 mL
selection buffer. GST-BRCT beads: a separate 400 µL of bead suspension was washed 3x with
GSH beads wash buffer. 1mL of 10 µM GST-(BRCT)2 was added and tumbled 1 hour at 4°C.
GST-(BRCT)2 bound beads were washed 2x with GST beads wash buffer and 1x with selection
buffer. The previously purified peptide-mRNA fusions were dissolved in 1200 µL selection
buffer.

Pre-clear: fusions were added to GST bound beads and tumbled 1 hour at 4°C.

Selection: the supernatant containing the library was transferred from the GST bound beads to
the GST-(BRCT)2 bound beads. With an additional three washes, the total volume transferred to
the GST-(BRCT)2 beads was 1300 µL. 13 µL of 10 mg/mL BSA was also added and the tube
was tumbled for 1 hour at 4°C. The beads were washed 3x with 1 mL selection buffer. Peptidefusions were eluted along with the bound protein by the addition of 6 x 100 µL freshly prepared
GSH elution buffer (250 mM Tris-HCl pH 9, 500 mM NaCl, 100mM L-glutathione reduced
(Sigma), 1% Triton X-100). Each addition of elution buffer was allowed to incubate for 5
minutes. Portions of selection input, flow through, washes, re-suspended beads and elution
fractions were quantified by scintillation counting of
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S-Met and used to monitor selection

enrichment. Elution fractions were combined and dialyzed overnight at 4°C into 0.1% Triton X79

100 prior to PCR amplification with Library FWD primer: 5’-TAATACGACTCACTAT
AGGGTTAACTTTAGTAAGGAGGACAGC-3’, and Library REV 5’-CTAGCTACCTATAG
CCGGTGGTGATGGTGATGGTGGCC-3’ primers. The amplified cDNA was then transcribed
and used for the subsequent round of selection. The scale of the second round of selection was a
1 mL translation, followed by rounds 3-8 that were started with 500 µL translation reactions.
Additionally, pre-clearing of the library bound to GST beads was only performed in rounds 1 and
2.
cDNA Sequencing. To analyze the results of the selection, cDNAs were amplified by PCR and
cloned into the pCR-TOPO vector (TOPO TA Cloning Kit, Invitrogen). Unnatural amino acids
were assigned on the basis of the tRNA/AARS pairs responsible for their incorporation into
peptides. For DNA and peptide sequence alignments and homology ranking, Jalview Version 2
was used.123

3.7 Summary
An mRNA display selection with 1.3 x 1013 peptide members was selected against a
recombinant GST fusion of the BRCA (BRCT)2 domain. After 8 rounds, the surviving peptides’
sequences showed 7 sequences occurring multiple times, making up more than 80 % of
determined sequences. No evidence of cyclization is apparent from the sequences, with an
UNAA presence biased toward F26 and R1.

Future Directions. With peptide sequences in hand, it is necessary to rank the peptides by
affinity as well as to determine how tightly they bind. Where these peptides bind on the BRCT
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domain is also important for these peptides to be applied as inhibitors, and will need to be
investigated.
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CHAPTER 4. LIFE AFTER SEQUENCING:
RANKING THE TOP PEPTIDE HITS

Contributions:
ERW and David E. Hacker are responsible for peptide synthesis and purification.
ERW conducted all of the biacore, ITC and FP experiments.
David E. Hacker is responsible for the MS/MS experiments of cyclized peptides.
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Chapter 4: Life after Sequencing: Ranking the Top Peptide Hits
4.1 Introduction
After 8 rounds of mRNA-display selection against the (BRCT)2 domain of BRCA1, a
group of 85 sequences were determined. Nearly 80% of these sequences occurred more than
once and these 7 sequences were grouped together into families 8.1-8.7, ordered by frequency.
The D/E-X-X-F motif found in each of these sequences suggests these peptides may bind to the
same binding pockets as the pS-X-X-F peptides; however, before we can begin to investigate
such questions it is necessary to first confirm that these peptides bind to the (BRCT)2 domain.
There are many ways to determine a binding affinity, but before investing too much into
determining an exact affinity, a quick ranking of these peptides via a radiation spin assay was
pursued.

4.2 Equilibrium Ultrafiltration Binding Assay
Although there still isn’t an efficient means of incorporating the arginine analog
canavanine via solid phase peptide synthesis, synthesis of these peptides should be accessible via
in vitro translation. The scale of these reactions is small, but due to the presence of an
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S-

methionine it is sufficient for radiation spin assays to determine an approximate Kd of each
peptide.

This assay, as shown in Figure 4.1, involves the combination of a constant

concentration of radiolabeled peptide with varying concentrations of GST-(BRCT)2 protein.
Each sample will then be centrifuged in a 30,000 MWCO spin filter such that approximately half
of the solution remains in the top portion of the filter and half has been filtered through. By
calculating the fraction of peptide bound in each sample, a binding curve can be established
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Figure 4.1 Equilibrium Ultrafiltration Binding Assay. Various concentration of
GST-(BRCT)2 fusion protein is added to concentration of 35S-labeled peptide. After
incubation, the samples are centrifuged in 30,000 MWCO filters so that the sample is
divided, half filtered through the membrane, and half remaining in the top. A fraction
bound can ben calculated in each sample to achieve a binding curve.
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effectively ranking these 7 peptide families.
A cDNA representative of each peptide family was selected to generate the mRNA
template used for selection. A second peptide was chosen from family 2 that appeared to have a
second cysteine, which was called family 8.2c. All sequences chosen had a full length His-tag.
The glycerol stocks from sequencing were used to generate purified plasmid which was used in
PCR amplification of the cDNA insert (Figure 4.2). In vitro transcription was used to generate
the mRNA template used for in vitro transcription.
The resulting mRNA was used in 250-500 µL scale translation reactions. The large scale
reaction included
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S-methionine, but a 50 µL reaction was conducted in parallel for

characterization by MALDI. Many of the translation reactions suffered from poor yield for
unknown reason, and even those reactions with sufficient yield to conduct the spin assays were
not able to be characterized by MALDI. Typically we can detect as little as 1 pmol after ziptipping; however, not a single peptide produced from these mRNA templates was able to be
characterized even in reactions with yields greater than 1 pmol.

Despite the lack of

characterization, attempts at the radio-labeled spin assay were conducted with no observed
binding of any peptide. At this point it was decided to try to synthesize peptides with solid phase
peptide synthesis and characterized their binding to the (BRCT)2 domain via surface plasmon
resonance (SPR).

4.3 Surface Plasmon Resonance
Being able to synthesize peptides via in vitro translation should have been a rapid method
of synthesis and characterization; however efficiency was not its only advantage. As of this
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Figure 4.2 PCR Amplificaton of Library cDNA. One cDNA was selected for each of
the over represented families from the selection. After 24 rounds of PCR amplification,
the product was analyzed on a 1 % agarose gel. A) PCR amplification with primers from
selection. B) PCR product using shorter primers.
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writing, canavanine in an appropriately protected form for solid phase peptide synthesis (SPPS)
was not commercially available. Only one published report of the synthesis of a similar analog
Fmoc-canavanine(Mtr)-OH exists, and attempts to repeat the reported procedure have been
unsuccessful.124 Although progress is being made toward alternative routes of synthesis, it has
remained a formidable challenge owing largely to the lability of the O-N bond in procedures
typically used for Fmoc-arginine(Pbf)-OH as well as the lack of nucleophilicity of the guanidine
side chain of canavanine. With synthesis of peptides via in vitro translation an unsuccessful
endeavor, the decision was made to work toward synthesis via SPPS, with the possibility of
including arginine in the place of canavanine if necessary.
At this time it was hoped that we would soon be able to synthesize a suitably protected
canavanine, thus the peptide characterization began with those peptides without canavanine. The
first peptide chosen was peptide 8.3. Optimistic thinking that cell studies may quickly follow the
peptide ranking, a nuclear localization sequence (NLS) was added to the C-terminus of the
peptide making the full peptide sequence: MCNDF26TF26DKNL3NHHGSPKKKRKV, where
the underlined portion is the sequence of peptide 8.3 and the bold indicates the NLS sequence.
It was decided that surface plasmon resonance (SPR) would be a potentially quick
means of ranking the affinity of the peptides and would also give us kinetic information about
both the on and off rates of each peptide. SPR is one of the few techniques that allows
measurement of the kinetics of binding in real time, which is very powerful in characterizing a
binding affinity because both kon and koff can be easily determined. However, because this
measurement takes place on the surface of a chip surface binding artifacts can obscure the
solution phase kinetics.
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Amine coupling of the GST-(BRCT)2 to the chip surface was tried at first, but this
technique does not control for orientation of the protein on the chip surface. Direct coupling of a
protein makes the expected response from peptide binding to the protein more difficult to
estimate. Due to the multiple protein orientations, peptides will not be able to bind to every
protein. When peptide binds to the protein on the surface, the amount of peptide bound can be
correlated to the response units (RU) measured by the detector with the following equation.
R

R

sto ch o et y (

MW
MW ote

)
so

[4.1]

where Rmax is the the preducted total response of an assay in RU; Rligand is the response of the
bound protein in RU; the stoichiometry is equal to 1; MWligand is the molecular wieght of the
peptide, 2939 amu; and WMprotein
bound to the surface 51.2 kDa.

fusion

is the molecular weight of the GST-(BRCT)2 protein

Although directly coupling protein to the surface may

underestmate the maximum observable response from peptide binding, a more important
disadvantage of this technique is the inability to regenerate the bound peptide. Peptides are only
stable for a certain period of time, and it is advantageous to use fresh fusion peptide for each
analysis.
By switching to a configuration, shown in Figure 4.3, where an anti-GST antibody was
first coupled to the chip surface, the RU could accurately be predicted, and the fusion protein
could be freshly added for each experiment leading to more accurate analysis. From initial
experiments it was found that the RU resulting from peptide biding was orders of magnitude
greater than the expected RU. This likely indicates that the peptide is non-specifically binding to
the chip surface. The surface of the chip is a negatively charged dextran, so it is not surprising
that the positively charged NLS sequence would bind to the chip surface. This was confirmed
when a series of samples were run at various salt concentrations (Figure 4.4), where salt
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Figrue 4.3 SPR Experiment with α-GST Antibody. First a α-GST antibody is
covalently coupled to the dextran coated chip using standard amine coupling
chemistry. The (BRCT)2-GST fusion is then immobilized on the chip via interaction
with the antibody. Various concentrations of peptide are then flowed over the chip
and the resulting response is recorded.
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concentrations binding to the immobilized GST-(BRCT)2. Below is the sequence
of the peptide used in this study with the charges indicated.
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concentrations as high as 0.5 M NaCl were able to able to interrupt the non-specific interactions
bringing the RU down to the expected range. Although, there are other chip surfaces, such as an
amine based chip that could also eliminate the non-specific interaction, it may have been just as
simple to re-synthesize the peptide without the NLS which was likely causing the problem. It
was while making this decision, the instrument developed technical difficulties not readily
remedied, and the decision was made to pursue alternative means of peptide characterization.

4.4 Isothermal Titration Calorimetry
Because Isothermal Titration Calorimetry (ITC) is a solution based technique, the
presence of a NLS in theory should not interfere with characterization of peptide binding. The
NLS may alter the affinity of the peptide, but the same surface effects seen with SPR should not
be an issue. There was a significant learning curve when using ITC that can be mostly summed
up into a single concept: the ITC is a sensitive instrument and must be very clean to get accurate
results. This however, is often easier said than done, and in the case of our peptides this learning
curve was complicated due to the low affinity of the peptides. With ITC, there is a range of
affinities that are optimal for analysis, which can be defined by the following equation
c

[M]

[4.2]

where c is the Wiseman c parameter, n is the molar ratio, Ka is the association constant, and [M]t
is the total protein concentration.97
The optimal range for any ITC analysis is a c value between 10 and 100. At high c
values, the titration curve becomes too steep, and at low c values the curve becomes a shallow
almost linear slope.
impossible.

Both of these scenarios make accurate data analysis difficult, if not

As can be seen in the equation above, c is dependent up on n (reaction
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stoichiometry) and Ka (the association constant) which are inherent to the interaction under study
and therefore cannot be altered. This leaves the concentration of protein, [M]t, as the only
parameter that can be manipulated to produce an experiment with an optimal c value. For high
affinity inhibitors, the limitation of protein dilution to lower the c value is dependent upon the
amount of heat than can be measure in dilute solutions. For low affinity interactions, achieving
high protein concentration is limited by protein solubility. The GST-(BRCT)2 fusion protein that
was used for selection worked very well at the low concentrations needed for immobilization to
magnetic beads, or to the surface of an SPR chip, but for ITC it was necessary to have a protein
concentration as high as possible. Solubility of the GST-(BRCT)2 fusion became a significant
problem during attempts to achieve the high concentrations needed for ITC analysis.
Precipitation was observed during the concentrating process as well as during the actual ITC
analysis. One means of explanation for this observation is because GST exists as a dimer, and
the BRCA1 (BRCT)2 domain that displays weak homodimerization. At low concentrations,
solubility was not a significant problem, but as the concentration increased for ITC analysis,
perhaps these two dimerizing proteins formed a polymer resulting in significant precipitation.
Despite these hurdles, reasonably successful ITC analysis was achieved for 4 peptides (Figure
4.5). The only peptide with a discernable sigmoidal curve is peptide 8.3 D4pS. The plots that do
not appear sigmoidal have high error as they fall below the recommended c value for ITC
analysis.

4.5 MS/MS Analysis of Peptide Cyclization
While initial SPR and ITC studies were being conducted with peptide 3, DEH began
investigating what product was formed in the cyclization reaction with these peptides that did not
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Figure 4.5 Initial ITC Data with NLS Peptides. Shown here are the initial ITC
curves obtain for four peptides containing nuclear localization sequences (NLS).
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have a second cysteine. It was a bit surprising that none of the sequences contained a second
cysteine, and it was unclear the fate of mono-Cys peptides.

A peptide of the sequence

MCNDF26TF26DKNL3NHHGSPKKKRKV was subject to cyclization and analyzed by ESIMS/MS. The results of this analysis indicate cyclization is limited to an interaction between the
peptide’s N-terminal Met and Cys, forming a cyclic sulfonium group (Figure 4.6).

4.6 Fluorescence Polarization
After running into technical difficulties with the radiolabeled spin assay, SPR and ITC
analysis of peptides, it was determined that a fluorescence polarization (FP) assay might be the
best alternative to rank the peptides from selection. Like ITC, FP has some limitations with
regard to the range of binding affinities it can accurately measure. ITC is limited by its c value;
however, FP is often not suitable to measure low affinity proteins due to the high protein
concentrations needed to produce a full binding curve. In a typical assay, a fluorescently
labelled peptide is kept at a constant concentration with increasing concentration of protein. At
the high concentrations needed to examine low binding affinities, protein solubility and
aggregation begin to interfere with analysis due to non-specific light scattering that exists in
samples containing aggregates or with higher viscosity.

This rationale combined with the

simplicity of synthesizing a single fluorescently-labelled inhibitor instead of labelling each
peptide under study made a competition study an ideal means to rank the peptides. Although this
will not directly determine a binding affinity in terms of Kd, it will allow for determination of an
IC50 with respect to the known inhibitor. In other words, a competitive FP study will determine
the half maximal concentration of our competing peptides that can successfully prevent the know
inhibitor from binding.
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Figure 4.6 Proposed Cyclization Structure. This structure was proposed based on
MS/MS data of library peptide 8.3 cyclized with dibromoxylene. In the absence of
a second cysteine, it is thought that cyclization is occurring between the N-terminal
Met-Cys producing the sulfonium ion shown.
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FAM-β-A-pSPTF-NH2 is a known BRCA1 (BRCT)2 binding peptide that has been used
previously in FP competition assays.108 All competitor peptides from the library were generated
via SPPS and purified by HPLC, with verification by MALDI (See Appendix I). As of this
writing, protected canavanine suitable for SPPS has still not been successfully synthesized, so
each of the peptides characterized by FP has arginine where canavanine was present in the
peptide sequence. The major difference between the two molecules is their side chain pKas (Arg
pKa = 12.5, canavanine pKa = 7.0).125
Initial fluorescence polarization competition assays were conducted with representative
peptides in their full length, un-cyclized form. All assays utilized a thioredoxin (TR) fusion
protein, TR-(BRCT)2, which has superior solubility to the GST-(BRCT)2 fusion. SDS-PAGE
analysis of this proteins purity can be found in Figure 4.7. All seven peptides were tested in their
linear forms, and five of them were tested as cyclization products as solubility and stability
allowed. The curves resulting from this analysis can be found in Appendix II. The IC 50 values
determined for all twelve peptides can be seen in Table 4.1. Linear peptide 8.6 had the highest
binding affinity with an IC50 of 10.5 µM, binding twice as strongly as peptides 8.1 and 8.5, and
more than five-fold more strongly than any other peptide tested. The effect of cyclization had a
negative impact on affinity except in the case of peptide 8.1 where there was a neutral effect on
binding.

4.7 Discussion
In the selection sequences, no second cysteines were found in the random region, but
MS/MS analysis of a cyclized peptide revealed the presence of dibromoxylene cyclization
between the N-terminal Met-Cys. It is possible that the reactive sulfonium ion formed in
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Figure 4.7 SDS-PAGE Analysis of Purified Thioredoxin-(BRCT)2 Fusion
Protein. Analysis of the purified BRCT fusions by SDS-PAGE and staining
with Coomassie Blue shows proteins estimated to be >95% pure. The
expected mass of TR-(BRCT)2 is 42.9 kDa.
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Peptide

Sequence

IC50 (µM)

8.6

MCTIDFDEYRFRKT

10 ± 1

8.6c

MCTIDFDEYRFRKT

24 ± 2

8.1c

MCNDFIFRRSTFRA

25 ± 2

8.1

MCNDFIFRRSTFRA

24 ± 2

8.5
8.2
8.4

8.7
8.3
8.7c
8.4c
8.3c

MCYDFDTTNDHTFI
MCSDFIFSRRTYTF
MCHNDFAFAKTSLY

MCDFQFRKPSTTIY
MCNDFTFDKNLNHH
MCDFQFRKPSTTIY
MCHNDFAFAKTSLY
MCNDFTFDKNLNHH

26 ± 2
49 ± 5
56 ± 4

56 ± 6
99 ± 8
122 ± 9
125 ± 12
142 ± 15

Table 4.1 Ranking of Peptides from Selection. The linear form of all seven
peptides and the cyclized form of five, were tested in a competition assay with
FAM-β-A-pSPTF, a peptide known to bind the (BRCT)2 domain.
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cyclization could result in a covalent linkage upon binding to the protein if the right
functional groups were near; however, our Biacore data did not support a covalent mechanism.
The seven peptide families in both linear and cyclized forms were eventually ranked by
their binding affinity by FP after technical hurdles were uncovered with other techniques.
Comparison of the binding affinity of linear and cyclized peptides with FP showed that
cyclization had a negative effect on binding affinity in all cases except peptide 8.1 where the
affect was neutral. Since 40% of the library should have had a second cysteine somewhere in the
random region, and none of these were selected seems to suggest that the (BRCT)2 domain
prefers a more extended binding motif. The question of whether the entire length of these
peptides is required to bind remains unanswered, but suggests that the full length may be
necessary, or that the presence of cyclization with a second cysteine actually produced peptides
in unfavourable binding confirmations.
Although each of the techniques employed here are suitable for ranking the peptides from
selection based on their approximate affinities, technical challenges were a significant hurdle in
this endeavor. The radiation spin assay could have allowed us to easily rank the peptides as well
as to examine the effects of UNAA compared to the all-natural analogs. The frequently poor
yields obtained from these reactions as well as the inability to characterize these peptides by
MALDI-TOF led us to pursue techniques using peptides made with SPPS. Initially peptide 8.3
(which was chosen due to its lack of canavanine which was not able to be incorporated in the
solid phase) was examined by SPR in both its linear and cyclized state with the addition of an
NLS. In the end, the positive charge of the NLS led to significant non-specific interaction with
the negatively charged SPR chip. By the time this was confirmed, technical difficulties with the
instrumentation led us to pursue other avenues of analysis.
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Testing these same peptides with ITC led to less than optimal results partially due to
technical problems with instrument maintenance and GST-(BRCT)2 solubility, but also because
these peptides have low enough affinity, perhaps affected by the presence of the NLS, that they
are outside the optimal range of analysis for ITC. It was then decided that all 7 peptides should
be synthesized on the solid phase without an NLS or any other modification with arginine in the
place of canavanine. These peptides in their linear and cyclized forms were ranked by IC 50
through a competitive FP assay against a known inhibitor FAM-β-A-pSPTF. The FP curves
collected can be found in the Appendix II. The highest affinity peptide was fond to be the linear
form of peptide 8.6. This peptide will be the subject of further investigation into how this
peptide binds to the (BRCT)2 domain.
Unfortunately, not being able incorporate the canavanine that was present in selection
leaves many questions unanswered. Linear peptide 8.6 had the highest affinity with an IC 50 of
10.5 µM. Would this have been lower if canavanine were in place of arginine? Inclusion of
arginine means that this residue has a positive charge where none was present during selection,
as well as a carbon where an oxygen would be which could alter potential hydrogen bonding
interactions. Other arginine analogs such as citrulline could be used to approximate the effect of
canavanine’s neutral charge, but the only current means to investigate peptides with canavanine
is to synthesize them with in vitro translation.

4.8 Experimental
Generation of peptides with in vitro translation. Glyerol stocks from selection were grown up
overnight in 1ml LB containing kanamycin. The next day the cultures were removed from the
shaker and cells were collected via centrifugation. The plasmids were purified with Qiagen
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miniprep. PCR amplification was conducted with the same primers used for selection with serial
dilutions of the template plasmid with 24 rounds of amplification.

The primers used for

amplification of families, 1, 4, 5, 6, and 7 had the following sequences: FWD TAATACGACTC
ACTATAGGGTTAACTTTAGTAAG, REV CTAGCTACCTATAGCCGGTGGTG. A 500 uL
in vitro transcription reaction was set up for each PCR product as previously described.103 The
resulting mRNAs were purified by urea-SDS-PAGE and electroelution followed by ethanol
precipitation. 500 uL scale in vitro translation reactions were conducted with each mRNA
template as previously described.103

Radiation Spin Assay. A constant concentration of 35S-methionine containing peptide from in
vitro translation reactions was incubated with different concentrations of GST-(BRCT)2 fusion
protein in 200 L selection buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 4 mM MgCl2, 0.25%
Triton X-100) while tumbling for 5, 20, 60 and 120 minutes at 4C in a YM-30 filter. After
incubation samples were spun at 12200 rpm for 75 seconds until approximately half of the
volume had been filtered into the bottom collection chamber. The radioactivity in the top and
bottom chamber was determined by removing 75 L from each. From this the total peptide
(“top”) and free peptide (“bottom”) concentrations were used to calculate the fraction of peptide
bound from the formula fa = [bound peptide]/[total peptide], where [bound peptide] is the
concentration of peptide bound to the GST-(BRCT)2 fusion protein and [total peptide] is the total
peptide concentration, by substituting top-bottom for [bound peptide] and top for [total peptide].

Peptide synthesis. The peptides were synthesized using a Liberty Automated Microwave
Peptide Synthesizer (CEM). The peptides were synthesized on Fmoc-PAL-PEG-PS Resin

101

(Applied Biosystems) using N-α-Fmoc-protected amino acids (CEM or AAPPTEC) or unnatural
N-α-Fmoc protected amino acids (Chem Impex). After each coupling step a capping step was
performed using 20% acetic anhydride (Fisher Certified ACS). The peptides were cleaved from
the resin using trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water
(92.5:2.5:2.5:2.5) with incubation at room temperature for 3 hours, and the resin was filtered off.
The filtrate containing the crude peptides was precipitated with cold ether, and collected by
centrifugation. The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher
HPLC Grade) and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by
freezing and lyophilization. The peptides were then purified by reverse phase HPLC using a
Shimadzu Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water
(A) and CH3CN (B) as the mobile phase with monitoring at 215nm or 264nm. A typical gradient
was 10-100% B over 30 minutes, but was adjusted for each peptide. MS data was collected
using a Micromass MALDI-R spectrometer.
MALDI-TOF Analysis.

HPLC fractions were prepared for analysis by 1:1 dilution in a

1:0.99:0.01 CH3CN:H2O:TFA solution containing 10 mg/mL α-cyano-4-hydroxy-cinnamic acid
(CHCA). After spotting on the sample plate, samples were allowed to co-crystallize by slow
evaporation at rt. Samples resulting from translation reactions were desalted and concentrated
with ZipTipC18 Pipette Tips (Millipore) according to the manufacturer’s protocol.
Peptide Cyclization with α-α’-dibromo-m-xylene:

A 50 mL oven-dried flask was charged

with water (19.34 mL) and acetonitrile (5.28 mL) and was deoxygenated by bubbling Argon for
10 min. Then 200 mM ammonium bicarbonate (3.5 mL, pH 8.4), tris-carboxyethylphosphine
(TCEP) (2.0 mg, 7.0 μmol) in 3.5 mL water and peptide (10 mg, 3.5 μmol) were added and the
reaction was kept under argon. After 30 min, α-α’-dibromo-m-xylene linker (10.2 mg, 38.6
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μmol) was added as a solution in 3.5 mL of acetonitrile. The reaction was incubated at rt and
monitored by MALDI-TOF. After 2 h, β-mercaptoethanol (BME) (13.7 mg, 176 μmol) or
dithiothreitol (DTT) (27.1 mg, 176 μmol) was added to quench unreacted linker, which
serendipitously led to formation of peptide-linker-BME (or DTT) adducts upon concentration
during lyophilization. Omission of the quench step resulted in the desired α-α’-dibromo-mxylene cyclized peptide product. The reaction was then frozen and lyophilized. The resulting
white powder was dissolved in 25% acetonitrile and purified by reverse phase semi-preparative
HPLC under the following conditions. Column: Vydac 218TP52210 22 x 100 mm: Flow rate: 10
mL/min: Solvents: A=water/0.1% TFA, B=acetonitrile/0.1% TFA): Gradient: 10 min at 10% B,
30 min at 10-55% B. Injection occurred at 5 min. 4.8 mg (1.63 μmol, 47%) of pure, unquenched
product was recovered.
Determination of Protein and Peptide Concentrations. All protein and peptide concentrations
were determined using their UV absorbance at 280 nm according to the method of Gill and von
Hippel
1
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. Extinction coefficients: GST-(BRCT)2 = 76810 M-1cm-1; TR-(BRCT)2 = 50070 M-

cm-1; FAM = 75800 M-1cm-1; Peptides = 1280 M-1cm-1 (each contains a single Tyr).

Surface Plasmon Resonance. All experiments were performed at 25 °C on a Biacore 2000
instrument (GE Healthcare). Immobilization of either GST-(BRCT)2 fusion or α-GST antibody
was achieved via amine coupling to a CM5 chip (GE Healthcare) per the manufacturer’s
instructions (Amine coupling kit, GST capture kit, GE Healthcare). Peptides were diluted in
HBS-EP running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005%
Surfactant P20) with the adjusted NaCl concentrations as indicated.

Isothermal Titration Calorimetry. ITC experiments were performed on an ITC200 calorimeter
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(Microcal Inc.) in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4. Experiments were
carried out by titration of 200-400 µM peptide in the syringe into 20-30 µM TR-BRCT protein in
the sample cell. The cell was thermostated at 25 °C and the syringe was stirred at 400 rpm. Each
titration consisted of 20 injections of 2 µl except for the first addition which was only 0.5 µL.
This first data point was deleted prior to data analysis. Control experiments consisted of titration
of peptide into buffer alone to determine the heat of dilution which was subtracted from the data
collected from the peptide into protein titration. The resulting data was fitted using a one-set
binding-site model analysis using Origin 7 software (Microcal Inc.) to obtain binding
stoichiometry (N), association constant (Ka), change in enthalpy (ΔH).

ΔG and ΔS were

calculated with the following equations: ΔG = -RT*ln(Ka) and ΔS = (ΔH – ΔG)/T.
Cloning and Protein Expression. To prepare an N-terminal thioredoxin fusion with C-terminal
His-tag (TR-BRCT). The pGEX-4T-1 vector containing the BRCA1 (BRCT)2 domain (amino
acids 1646-1859)119 previously described (Chapter 3) was digested with BamHI and XhoI and
ligated into the modified pET32a.127 After transformation into Rosetta 2(DE3) strain of E. coli,
cells were induced using IPTG and expressed overnight at 18 °C. The recombinant protein was
purified on FPLC using nickel affinity chromatography with Chelating Sepharose Fast Flow
resin (GE Healthcare) and elution with a gradient of imidazole (50 mM phosphate pH 8.0, 300
mM NaCl, 25 mM imidazole wash, 250 mM imidazole elute) followed by chromatographic
isolation by size exclusion chromatography with HiLoad 26/60 Superdex 75 prep grade resin
(GE healthcare) in Buffer A (300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4). The
resulting fusion proteins had a yield of 20 mg/L and were >95% pure as estimated by SDS–
PAGE analysis. Proteins were stored at -80 °C after dialysis in 1L enzyme storage buffer (50
mM HEPES-KOH pH 7.6. 100 mM KCl, 10 mM MgCl2, 7 mM BME, 30 % glycerol).
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Determination of IC50 with Fluorescence Polarization. The indicated amounts of competing
peptide were added to a total of 150 µL containing 2.5 µM TR-(BRCT)2 and 20 nM FAM-β-AlapSPTF in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4. The samples were incubated
at room temperature for 2 hours.

The samples were then analyzed in a 100 µL quartz

fluorescence cuvette using a Cary Eclipse Fluorescence Spectrophotometer (Varian Instruments)
with polarizing lens attachment. The G-factor was experimentally determined with sample
containing 20 nM FAM-β-Ala-pSPTF in the same buffer. Anisotropy values were automatically
calculated by the accompanying Advance Reads software.

After plotting anisotropy versus

peptide concentration, an IC50 was determined as the peptide concentration at which 50% of the
FAM-β-Ala-pSPTF was bound by fitting to the four parameter logistic equation using SigmaPlot
11.

4.9 Summary
On the road to ranking the top 7 hits from the library selection many technical hurdles
were encountered. After attempting radiation spin assay, SPR, and ITC, finally FP was used to
rank the peptides in a competition assay with a phopsphoserine containing peptide known to bind
to the BRCA1 (BRCT)2 domain.
Future Directions: Now that an initial ranking has been achieved, there are many more
questions remaining with regard to the highest affinity peptide: linear peptide 8.6. Whether or
not the full length of the peptide is necessary will be investigated as well as mutational analysis
of individual amino acids. The presence of an E-X-X-F motif of this peptide suggests it may
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bind in the same pockets as the pS-X-X-F motif, and the importance of these amino acids can be
partially addressed through alanine mutations.
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CHAPTER 5. WHERE’S THE PHOSPHATE?: INVESTIGATION OF PEPTIDE 8.6
BINDING MECHANISM THROUGH MUTATIONAL ANALYSIS
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5.1 Introduction
The ultimate goal for this project was to discover a non-phosphorylated peptide that binds
to the (BRCT)2 domain of BRCA1 in the same location as proteins known to interact with this
domain. The presence of our D/E-X-X-F motif in each peptide is an encouraging indication that
the selected peptides are in fact competitive inhibitors due to the analogous pS-X-X-F motif that
is currently thought to be necessary for proteins binding to this domain. Presence of a similar
motif does not guarantee binding and needs further testing to support this hypothesis. The focus
of this chapter is mutational studies with the aim of understanding how the highest affinity
peptide 8.6 is binding to the (BRCT)2 domain, as well as attempts to improve up on the affinity
of this peptide.

5.2 Examination of Peptide 8.6 Truncation
With linear peptide 8.6 being the highest affinity peptide from selection it was decided to
focus all further efforts on this peptide. A series of truncated peptides were made and their
affinities were compared to linear peptide 8.6 via the same fluorescence polarization assay. The
results from these studies can be found in Table 5.1. It was first investigated to what extent the
putative core amino acid, DEYRF and FDEYRF could bind to the (BRCT)2 domain, but these
peptides had little to no binding to the protein. This provides evidence that amino acids outside
the core tetrapeptide provide significant binding interactions, which is in contrast to previous
phosphoserine-containing peptide binders.109 To determine the contribution of both termini of
the peptide we made a few truncation mutants. Further truncation mutants showed that removal
of the C-terminal RKT led to a small 2-fold increase in IC50 while N-terminal truncation led to a
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Peptide
8.6

Sequence

IC50 (µM)

MCTIDFDEYRFRKT

10.5 ± 1.0

8.6 7-11

DEYRF

>500

8.6 6-11

FDEYRF

>500

8.6 1-11

MCTIDFDEYRF

8.6 7-14
-MC

23.8 ± 1.9

DEYRFRKT

274 ± 59

TIDFDEYRFRKT

25.5 ± 5.4

Table 5.1 Truncation Analysis of Peptide 8.6. Peptide 8.6 was incrementally
truncated to investigate whether the full length of the peptide was necessary to
achieve its highest binding affinity. These peptides were tested via an FP
competition assay and the IC50s resulting are shown here. 4-F-phenylalanine is
indicated by red lettering.
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25-fold increase. Therefore the N-terminal 6 amino acids are more important for binding than
the C-terminal “RKT.” Another peptide was made to investigate the presence of the N-terminal
fixed
Met-Cys. As part of the non-random region, this was not optimized from the library other than
its position relative to the D/E-X-X-F motif. Removal of these amino acids resulted in a twofold decrease in affinity which is the same effect as “blocking” these amino acids with
cyclization. This was yet another indication that the full length is necessary to achieve the
highest affinity.

5.3 Mutational Analysis of Peptide 8.6
For results of FP analysis, see Table 5.2. To investigate whether the EYRF motif is
binding in the same manner as the pS-X-X-F motif in other known peptides we mutated the Phe
to Ala (F11A) and changed the Glu to Ala (E8A). Both mutants showed a dramatic increase in
the IC50 value, highlighting their importance for binding. It is interesting that the individual
amino acids in this motif are necessary yet not sufficient for binding.
If the elimination of the glutamic acid had such a dramatic decrease in binding, then what
effect would the incorporation of a phosphoserine have? In previous studies the mutation of a
phosphoserine to the phosphomimetic amino acids glutamic and aspartic acid has led to a several
order of magnitude decrease in binding if not complete elimination of binding.128 Because of
these results we were surprised that 8.6 E8pS peptide had only a three-fold increase in binding
affinity. Because of the small increase, it was hypothesized that the presence of phosphoserine
perhaps changed the mechanism of binding. The truncation studies showed that the N-terminal
MCTID was important for peptide binding, and this same truncated peptide with an EpS

110

Peptide

Sequence

IC50 (µM)

8.6

MCTIDFDEYRFRKT

10.5 ± 1.0

8.6 F11A

MCTIDFDEYRARKT

356 ± 35

8.6 E8pS

MCTIDFDpSYRFRKT

3.45 ± 0.34

8.6 E8A

MCTIDFDAYRFRKT

> 300

8.6 E8pS 8-14

pSYRFRKT

2.73 ± 0.09

8.6 All Natural

MCTIDFDEYRFRKT

4.54 ± 0.22

Table 5.2 Mutational Analysis of Peptide 8.6. In attempt to investigate
whether peptide 8.6 binds in the same manner as native (BRCT)2 domain
binders, peptides with key mutations were analyzed via an FP competition
assay. The results are shown here. 4-F-phenylalanine is indicated by red
lettering.
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substitution had an even lower IC50 than the full length 8.6 E8pS peptide. Could the presence of
the phosphate change the way this peptide binds? Additionally an all-natural (AN) version of
Peptide 8.6 was tested to probe the effect of the 4-fluoro-Phe. Unfortunately canavanine was
unable to be incorporated in these peptides, so its importance is currently unable to be examined.
Some previous investigations of other hydrophobic amino acid substitutions for phenylalalanine
in the pS-X-X-F motif indicate that this hydrophibic binding pocket is quite selective and no
analogs were found to be superior to phenylalanine.128b Although none of the phenylalanine
analogs tested was as small of a modification as a single fluorine, the FP data from AN 8.6
indicates elimination of the two fluorines resulted in better binding.

5.4 Hybridization of Peptides 8.1 and 8.6
Given that the random region is only twelve amino acids in length, one can’t help but to
wonder what might have been found if the random region had been longer. The study of
truncated peptide 8.6 seems to indicate than the extended linear confirmation is necessary for
high affinity binding. Not every peptide has the same placement of the D/E-X-X-F domain, so is
it possible to generate a higher affinity peptide than any found in selection by hybridizing our
highest affinity peptides through mixing and matching those amino acids outside the core
domain?
Peptides 8.1 and 8.6 are the two highest affinity peptides from the selection and these
peptides have significantly different placement of the E/D-X-X-F domain. Combining the long
N-terminal portion and core of peptide 8.6 that has shown to be important with the long Cterminal portion of peptide 8.1 did not result in a peptide with higher affinity than peptide 8.6
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(See Table 5.3). Although a disappointing result, it also seems likely that the length of this
peptide (18 amino acids) may create additional contacts, but also increases the entropic cost paid
in binding. Entropic cost in mind, another hybrid peptide was created where the shorter Nterminus of peptide 8.1 was combined with the core and shorter C-terminus of peptide 8.6. Since
the N-terminus of peptide 8.6 was shown to be critical it was surprising that this short peptide
was only weaker by a factor of 2-3. This may suggest that the N-terminal MCN of peptide 8.1
makes important contacts with the (BRCT)2 domain. In addition to the D/E-X-X-F motif, the
majority of the peptide families also have a threonine somewhere in the C-terminal sequence.
Could the hybridization of the N-terminal portion of peptides 8.1 and 8.6 result in a higher
affinity peptide? The N-terminal RKT was added to the end of hybrid peptide 2, but this actually
resulted in a slight decrease in binding affinity rather than an increase.
Mixing and matching of peptide pieces outside the core domain did not prove successful
in producing higher affinity peptides, but questions remained about the effect of amino acids in
the core domain. Instead of substituting any individual core domain for another, these were
investigated incrementally. Comparisons were again made between peptides 8.6 and 8.1 because
they were the highest affinity peptides, but peptide 8.1 also contains the core domain that
occurred the largest number of times in selection since the DFIF motif found in 8.1 is also the
core domain of 8.2. First, an E8D mutation was made of peptide 8.6 to compare the two
phosphoserine analogs, but this mutation was not beneficial indicating preference of the glutamic
acid. The difference between the core domains primarily lies in the amino acids selected for the
“X-X” portion of the core domain. A substitution of the FI from peptide 8.1 for the YR in
peptide 8.6 also had a minimally negative effect providing further evidence that the core domains
are not completely interchangeable. Another interesting observation in the sequence of peptide
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Peptide

Sequence

IC50 (µM)

8.6 All Natural

MCTIDFDEYRFRKT

4.5 ± 0.2

8.1, 8.6 Hybrid

MCTIDFDEYRFRRSTFRA

18.6 ± 0.8

8.6 E8D

MCTIDFDDYRFRKT

9.6 ± 0.5

8.6 Y9F, R10I

MCTIDFDEFIFRKT

7.0 ± 0.4

8.6 D7N

MCTIDFNEYRFRKT

5.6 ± 0.1

8.1, 8.6 Hybrid 2

MCNEYRFRKT

12.7 ± 2.0

8.1, 8.6 Hybrid 3

MCNEYRFRKTFRA

14.5 ± 2.3

Table 5.3 Analysis of Hybridized Peptides. Six peptides were synthesized that
were hybridized sequences of peptide 8.1 and 8.6. These peptides were
subjected to an FP competition assay and the resulting IC50 are shown in this
table.
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8.1 is the presence of an asparagine -1 from the DFIF. This D7N mutation was tested and was
found to be a nearly neutral mutation. Although the D7N mutation may not have made an
improvement of peptide affinity, but it did show an improvement in solubility, which may be
useful in later studies.

5.5 Examination of Highest Affinity Peptides by ITC
Ranking peptides via their IC50 values proved useful for comparison between peptides;
however, to compare these peptides to other known binders determination of a Kd is necessary.
Another point to consider is that it is well known that IC50 values approaching the Kd of a
fluorescent ligand (in our case 2.3 µM)108 are obscured by the fluorescent ligand’s intrinsic
affinity,129 so comparisons between ligands with IC50 values approaching the Kd of the
fluorescent ligand are not reliably quantitative.
Further characterization of peptides (8.6, AN, 8.6 E8pS, and 8.6 8-11 8EpS) by ITC was
conducted (Figure 5.1). The relative ranking of the binding affinity of the three peptides is
roughly the same as that determined by FP (E8pS > AN > 8.6). The relative entropic and
enthalpic contributions to binding were also determined (Table 5.4, Figure 5.2). The binding of
all three peptides is driven by large, negative ΔH values. Surprisingly, the glutamic acidcontaining peptides from our libraries have more negative ΔH values than E8pS. One potential
rationale for this increase in ΔH is that the glutamic acid containing peptides form additional
contacts (presumably at the N-terminus) with the protein which result in the more favorable
value. This pattern holds true except for the E8pS 8-14 peptide that actually has a larger
negative ΔH than the full length E8pS peptide.
The binding of all four peptides have negative ΔS values. The entropic term of binding is
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Figure 5.1 ITC Analysis of Highest Affinity Peptides. The curves shown
above are the ITC curves collected for four of the highest affinity peptides
uncovered from selection and mutation of peptide 8.6.
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CtIP-myc Cell Lysate
GST-(BRCT)2

No Lysate

No GST-BRCT
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Figure 5.2 Inhibition of (BRCT)2 and CtIP in Interaction in Cell Lysate. A
pull down study was conducted in which CtIP-myc was over expressed in cell
lysate and bound to immobilized GST-(BRCT)2 on agarose. This interaction
was inhibited with increasing concentrations of AN peptide 8.6.

7

118

correspondingly less favorable for the peptides containing Glu vs. pSer except in the
E8pS 8-14 peptide. Before testing of the truncated pSer peptide, it was hypothesized that the Glu
peptides are gaining additional N-terminal contacts not found in E8pS. These additional contacts
would be thought to increase the entropic cost of binding; however, this model does not fit given
the increased entropy of binding found in the shorter E8pS 8-14 peptide.
Finally, it is interesting that the replacement of two fluorines with two hydrogens (8.6 to
AN) results in a significant increase in ΔS. This is the opposite of what is typically observed
with fluorine substitutions, since the more hydrophobic fluorinated molecules typically have
more favorable entropy due to desolvation of their increased hydrophobic surface.130 Although
this could be explained by different solution structure preferences of the two peptides, we think it
is more likely that the increase in entropy results from more flexibility in the binding of Phe vs.
the slightly more sterically demanding 4-F-Phe. We are currently pursuing crystallographic
studies to investigate these hypotheses.

5.6 Inhibition of CtIP-BRCA1 Interaction in Cell Lysate
In order to assess the ability of the highest affinity non-phosphorylated peptide (AN) to
inhibit protein-protein interactions in cell lysates, a known BRCA1 (BRCT)2 binding partner
phospho-CtIP-myc131

was overexpressed in 293T cells and captured with purified GST-

(BRCT)2 fusion in the presence of varying concentrations of the peptide.

Proteins were

separated by SDS-PAGE and analysed via western blotting (Figure 5.3). A dose-dependent
inhibition of the CtIP-BRCT complex was observed, resulting in near complete abrogation of
this interaction at 50 µM.
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5.7 Discussion
Mutational Analysis of Peptide 8.6. Truncation of peptide 8.6 down to its core DEYRF
domain resulted in nearly complete abolishment of binding. No truncation mutations were found
that maintained an IC50 as low as the full length peptide, but deletions of the N-terminal and Cterminal regions outside of the core domain showed that overall the N-terminal region of the
peptide plays a large role in the interaction. The pSer and Phe of native peptides are generally
regarded as being necessary and sufficient for binding to the (BRCT)2 domain. Therefore it
stands to reason that if our D/E-X-X-F peptides are biding in the same pockets, elimination of
the key E and F via alanine mutation might also abrogate the interaction.
Despite the inability of the core domain to bind alone, these alanine mutations had a
significant impact on binding affinity indicating they are playing a very important role. It is
interesting that the E8pS mutant did not have a more dramatic increase in binding affinity. We
also attempted to generate a higher affinity peptide by recombining the highest affinity
sequences from selection. Although none of these attempts generated a higher affinity peptide, it
is interesting to note that the point mutations had much less of an effect on binding that any
attempts to recombine whole sections of the sequences.
ITC analysis showed that AN 8.6 had a Kd of 1 µM making this the tightest nonphosphorylated (BRCT)2 domain binder discovered to date. The thermodynamic information
from the ITC analysis raised more questions than it answered about the potential binding
mechanism of these peptides.

Hopefully these questions can be answered with the

crystallographic studies that are underway.
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Comparison to current inhibitors. Our peptide may not be the tightest-binding molecules
discovered to date that bind to the (BRCT)2 domain, but there is much more to drug design than
affinity. A molecule without a phosphate is arguably much more cell permeable and stable,
which is a significant advance in the quest for an inhibitor of BRCA1.79 Small molecule screens
have resulted in peptides in the mid-micromolar range, yet despite fewer drug delivery issues
with small molecules they were unable to effectively inhibit BRCA1 function.132 With small
molecules seemingly unable to do the job, many phosphopeptides have been tested that are
higher affinity that the previous small molecules, and have been shown to inhibit (BRCT)2
binding proteins in cell lysate. Translation of these effects into cells has been much more of a
challenge. Even the highest affinity peptide required high (100 µM) concentration and had
minimal inhibitory function. The trade-off in the history of BRCA1 (BRCT)2 inhibition seems to
have been presence of a phosphate or an inhibitor. Our highest affinity peptide is not close to the
40 nM affinity achieved with phosphopeptides, but how tight does the affinity need to be?

Comparison to Native (BRCT)2 binding partners. In the development of inhibitors it is usually
the goal to develop a molecule that will bind to the desired site with the tightest affinity possible.
Affinity is important, but so is cell permeability and stability. A lower affinity inhibitor may be
more affective in the end depending on the system. There are several known proteins that bind
to the (BRCT)2 domain, and of these the proteins BACH1 and CtIP currently have the highest
affinity (see Table 5.5). Several studies have been conducted reporting the binding affinity via
ITC for these interactions. For BACH1 reports have ranged from 0.9 to 0.17 µM and for CtIP
reports are a bit higher ranging from 3.7 to 1.32 µM. Thus our non-phosphorylated pepeptide is
in the same range as the natural protein binders.
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Table 5.5 Peptides Known to Bind to the (BRCT)2 Domain. This table is a list of peptides
known to interact with a reasonably high affinity with the (BRCT)2 domain of BRCA1.
Peptide

Sequence

Affinity (µM)

Reference

p-ACC1

DSPPQpSPTFPEAGH

5.2

133

1

Ac-pSPTF-CONH2

2.51

128b

CtIP

PTRVpSPVFGAT

1.32-3.7

134

7

Ac-pSPVF-CONH2

1.62

128b

AN Peptide 8.6

MCTIDFDEYRFRKT

1.0

BACH1

ISRSTpSPTFNKQ

0.17-0.9

134a, 135

18

Ac-pSPTF-COOH

0.19

128b

19

Ac-pSPVF-COOH

0.29

128b

15
*pSPVF-COOH
0.04
48a
134, 135c
* N-terminal constrained by a 3-carbon linker with a phenyl ring .
These affinities are
quite similar to the peptides discovered with this selection. Although a higher affinity inhibitor
is desirable, and will be a future direction for this work, given that the affinities of BACH1 and
CtIP for this domain are in the low micromolar and high nanomolar range, our peptide will likely
have a significant functional improvement with advancements in its current affinity.

Functional Analysis of Peptide 8.6. Perhaps the most important result from these studies, is
the initial demonstration that AN 8.6 can function as an inhibitor of BRCA1 (BRCT)2
interactions in cell lysates in a dose dependent manner. Although this study does address
protease resistance of the peptide due to the presence of protease inhibitors in the assay, it does
lend support to the specificity of the inhibitor. If non-specific binding were to be significant,
much larger quantities of the peptide would be needed to inhibit the (BRCT)2-CtIP interaction.
As it stands here the concentration needed to significantly inhibit the interaction approximates
the Kd measured by ITC.
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It is unlikely that we would have been able to find peptide 8.6 if we had made a library of 8
randomized AAs since the N-terminus through AA F11 are required for binding. However, the
extreme diversity of our peptide libraries has allowed us to find tight-binding nonphosphorylated inhibitors when other library approaches failed. Given enough diversity, binders
to challenging targets can be uncovered, including those previously requiring phosphoserine.

5.8 Experimental
Peptide synthesis. The peptides were synthesized using a Liberty Automated Microwave
Peptide Synthesizer (CEM). The peptides were synthesized on Fmoc-PAL-PEG-PS Resin
(Applied Biosystems) using N-α-Fmoc-protected amino acids (CEM or AAPPTEC) or unnatural
N-α-Fmoc protected amino acids (Chem Impex). After each coupling step a capping step was
performed using 20% acetic anhydride (Fisher Certified ACS). The peptides were cleaved from
the resin using trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water
(92.5:2.5:2.5:2.5) with incubation at room temperature for 3 hours, and the resin was filtered off.
The filtrate containing the crude peptides was precipitated with cold ether and collected by
centrifugation. The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher
HPLC Grade) and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by
freezing and lyophilization. The peptides were then purified by reverse phase HPLC using a
Shimadzu Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water
(A) and CH3CN (B) as the mobile phase with monitoring at 215nm or 264nm. A typical gradient
was 10-100% B over 30 minutes, but was adjusted for each peptide. MS data was collected
using a Micromass MALDI-R spectrometer.
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Determination of Protein and Peptide Concentrations. All protein and peptide concentrations
were determined using their UV absorbance at 280 nm according to the method of Gill and von
Hippel
1
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. Extinction coefficients: GST-(BRCT)2 = 76810 M-1cm-1; TR-(BRCT)2 = 50070 M-

cm-1; FAM = 75800 M-1cm-1; Peptides = 1280 M-1cm-1 (for peptides containing a single Tyr); 4-

F-Phe = 500 M-1cm-1 (for peptides with no Tyr, but contain at least one 4-F-Phe).
Determination of IC50 with Fluorescence Polarization. The indicated amounts of competing
peptide were added to a total of 150 µL containing 2.5 µM TR-(BRCT)2 and 20 nM FAM-β-AlapSPTF in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4. The samples were incubated
at room temperature for 2 hours.

The samples were then analyzed in a 100 µL quartz

fluorescence cuvette using a Cary Eclipse Fluorescence Spectrophotometer (Varian Instruments)
with polarizing lens attachment. The G-factor was experimentally determined with sample
containing 20 nM FAM-β-Ala-pSPTF in the same buffer. Anisotropy values were automatically
calculated by the accompanying Advance Reads software.

After plotting anisotropy versus

peptide concentration, an IC50 was determined as the peptide concentration at which 50% of the
FAM-β-Ala-pSPTF was bound by fitting to the four parameter logistic equation using SigmaPlot
11.
Isothermal Titration Calorimetry. ITC experiments were performed on an ITC-200
calorimeter (Microcal Inc.) in 300 mM NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4.
Experiments were carried out by titration of 200-400 µM peptide in the syringe into 20-30 µM
TR-BRCT protein in the sample cell. The cell was thermostated at 25 °C and the syringe was
stirred at 400 rpm. Each titration consisted of 20 injections of 2 µl except for the first addition
which was only 0.5 µL. This first data point was deleted prior to data analysis. Control
experiments consisted of titration of peptide into buffer alone to determine the heat of dilution
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which was subtracted from the data collected from the peptide into protein titration. The
resulting data was fitted using a one-set binding-site model analysis using Origin 7 software
(Microcal Inc.) to obtain binding stoichiometry (N), association constant (Ka), change in
enthalpy (ΔH). ΔG and ΔS were calculated with the following equations: ΔG = -RT*ln(Ka) and
ΔS = (ΔH – ΔG)/T.
Preparation of Cell Lysates. HEK293T cells were cultured at 37 °C in DMEM (Gibco) medium
supplemented with 10% FBS and 1% pen-strep. The CtIP-myc expressing pcDNA3-5X vector
was as described.
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Five million 293T cells were transfected with 5 µg plasmid using an

Amaxa Nucleofector II (Lonza) according to the manufacturer’s protocol (program A-023). 5days post-transfection, total cell lysates were prepared in 1.5 mL RIPA buffer (10mM Tris pH 7,
1% Triton-X, 0.1% SDS, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 0.1% sodium
deoxycholate) containing 1:100 dilutions of Phosphatase Inhibitor Cocktails 2 and 3 (Sigma) and
1:100 dilution of Protease Inhibitor Cocktail for use with mammalian cell and tissue extracts
(Sigma). Cell lysates were used immediately for pull-down experiments.
Pulldown-Western. 40 µL of the commercial Glutathione magnetic bead suspension (Pierce)
were washed three times with 200 µL beads wash buffer (125 mM Tris-HCl pH 8, 150 mM
NaCl). To the washed beads, 200 µL of 250 nM GST-(BRCT)2 fusion protein was added and
incubated while tumbling at 4 °C overnight. Beads were then washed three times with 300 mM
NaCl, 2.7 mM KCl, 10 mM phosphate, pH 7.4, and 100 µL of peptide solution in the same
buffer was added. The samples were incubated at 4 °C for 1.5 hours. To these samples 100 µL
of cell lysate was added and incubation continued for another hour. The magnetic beads were
washed three times with RIPA with inhibitors, and boiled for 10 minutes in 1x Laemmli buffer
(BioRad) followed by separation on 10% SDS-PAGE in running buffer (25 mM Tris, 192 mM
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glycine, 0.1% SDS) and Western blotting.
Western Blot Analysis.

After separation by SDS-PAGE, proteins were transferred to a

polyvinyl difluoride membrane (PVDF, 0.45 mm, Immobilon-FL, Millipore) by wet transfer at
0.6A for 2 h with transfer buffer (25 mM Tris, 192 mM glycine). Subsequently, the PVDF
membranes were blocked in blocking buffer (0.1X PBS and 0.1 % casein, BioRad) for 1 hour at
room temperature with gentle agitation. The primary antibodies (mouse anti-myc, Cell Signaling;
rabbit anti-GST, Cell Signaling) were diluted 1:1000 in blocking buffer and incubated overnight
at 4 °C with gentle agitation. The blot was washed 3 x 15 min at room temperature with PBS-T
(1X PBS, 0.2% Tween). Bound antibodies were labeled using secondary antibodies (Invitrogen
goat anti-mouse AlexaFluor 680, Rockland goat anti-rabbit Dylight 800) in a concentration of
1:2000 in blocking buffer. After incubation for 1 hour at room temperature, three further washing
steps of 15 min each at room temperature in PBS-T followed. The protein was imaged and
quantified using the Odyssey Infrared Imaging System and application software version 3.0 (LiCor Biosciences).

5.9 Summary
None of the truncated version of peptide 8.6 that were tested had a binding affinity lower
than that of the full length peptide 8.6. This supports the hypothesis that none of the selected
library members had a second cysteine in their sequences due to a preference for an extended
linear conformation.

Mutational analysis supports the theory that the D/E-X-X-F motif is

important for binding and perhaps binds in the same site as the known pS-X-X-F motif.
Attempts to hybridize peptides 8.6 and 8.1 did not result in discovery of a higher affinity peptide,
but did uncover multiple nearly neutral mutations. In the end, the all-natural analog of peptide
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8.6 (AN 8.6) proved to be the highest affinity peptide found with a Kd of 1 µM. Initial in vitro
inhibition of the (BRCT)2 domain CtIP in cell lysate appears to shows that AN 8.6 is the first
good, non-phosphorylated inhibitor of BRCA1.

Future Directions: Cell studies with all-natural peptide 8.6 (AN 8.6) are needed to test its
potential as an inhibitor of BRCA1. Because this peptide uses natural amino acids it could be
over expressed in a cell as an alternative to delivery with a cell penetrating peptide tag or other
delivery means. Although, initial in vitro studies show that AN 8.6 can inhibit protein-protein
interactions of the (BRCT)2 domain, additional studies are needed to support the binding of this
peptide in the same binding cleft. Binding studies with protein mutations would be useful in
demonstrating this. A crystal structure of an 8.6 analog and the (BRCT)2 domain is also being
pursued and will hopefully provide definitive evidence of how the peptide is binding to the
protein surface. This study has also served as a proof of principle for using large mRNA-display
libraries for discovery of peptides that bind to a BRCT domain that is traditionally thought only
to bind phosphopeptides. This same technique could be applied to the many other BRCT
domains as well as other targets to select inhibitors of other protein-protein interactions.
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CHAPTER 6. OVERCOMING CURRENT LIMITATIONS:

EXPANSION OF DRaCALA TO PEPTIDES
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6.1 Introduction
The most difficult challenge faced in finding a non-phosphorylated peptide inhibitor of
the BRCA1 (BRCT)2 domain was actually characterizing the peptides that were discovered in
selection. This experience highlighted the shortcomings of many of the standard binding affinity
analysis techniques we use. Although many of these techniques have great power, the more
complicated a technique is the more prone to technical difficulties it becomes. Work by the Lee
lab produced a technique that has been named the differential radial capillary action of ligand
assay (DRaCALA) which provides a very simple means of characterizing the binding affinity of
DNA to protein based simply on their differential diffusion on nitrocellulose.136 Protein tends to
bind non-specifically to nitrocellulose, and the high negative charge of DNA results in its
diffusion across the membrane. In the experiments conducted by the Lee lab, radiolabelled DNA
in a constant concentration is mixed in samples with varying concentrations of an interacting
protein. After spotting only five microliters of each sample onto nitrocellulose, the amount of
bound DNA can be ascertained from the diffusion pattern. Any DNA bound to the protein will
be observed as a darker inner circle, while unbound DNA is seen as a diffuse outer ring, as seen
in Figure 6.1. The fraction of DNA bound can be calculated be the equation
[

(

)

]

[6.1]

where FB is the fraction bound, Vinner is the volume of the inner circle, Vouter is volume of the
outer circle, Ainner is the area of the inner circle, and Aouter is the area of the outer circle.
The simplicity of this technique has quite an appeal. Not only does it not require
expensive equipment that requires training and maintenance, but it also uses very small
quantities of material for each assay. The authors posit that this technique might be applied to
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Figure 6.1 DRaCALA Experiment. In the proposed DRaCALA experiments,
protein and fluorescent ligand are incubated together in a sample of small
volume. 5 µL of this sample is spotted onto a dry, untreated sheet of
nitrocellulose membrane. As the sample diffuses from the center spot, the
protein interacts strongly with the nitrocellulose and remains in the center. An
ideal ligand for this interaction would diffuse uniformly with the solvent away
from the center. If the ligand binds to the protein an inner and outer circle will
appear, as shown, upon visualization with a fluorescent scanner. From analysis
of this pattern a fraction bound can be calculated with Equation 6.1.
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small molecules, but with its many advantages, we wondered if it could be applied to peptides.
Nitrocellulose binds proteins which are chemically no different than peptides, except of course
for their size. It was hypothesized that there was likely some set of peptides that would have
sufficient diffusion on nitrocellulose such that a DRaCALA assay could be used to study their
binding affinity with proteins.

6.2 Diffusion of Peptides on Nitrocellulose
A set of test peptides was established to test for their ability to diffuse on nitrocellulose.
These peptides were designed to test for different characteristics, including charge and length
(Table 6.1). Instead of using radiolabelled peptides, each peptide was fluorescently labelled with
fluorescein as a means of detection. Each set of peptides was dissolved at various concentrations
in PBS and spotted onto nitrocellulose. After drying, each was scanned at the appropriate
wavelength to examine the diffusion pattern (Figure 6.2). It was thought that perhaps the longer
peptides would not readily diffuse on the nitrocellulose, but it was found that the approximately
neutral peptides all displayed a central ring upon spotting which indicates they did not freely
diffuse on nitrocellulose. It was however, found, that the small and negatively charged pSPTF
peptide did readily diffuse on nitrocellulose at all concentrations making it perhaps suitable for
binding affinity analysis with this technique.

6.3 Model Systems for Comparison to Current Techniques
After observing that BRCA1 peptide, FAM-β-A-pSPTF, could in fact diffuse readily
across the nitrocellulose even at the highest concentration of 1 µM, it was tested in a binding
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Figure 6.2 Test of Peptide Diffusion on Nitrocellulose. The fluorescently labeled
peptides indicated (whose sequences can be found in Table 6.1) were spotted at
the concentration indicated onto dry, untreated nitrocellulose and examined on a
fluorescence scanner. Each spot is the result of 5 µL of sample.
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study with the thioredoxin (TR) fusion of the (BRCT)2 domain. Solutions with 20nM of FAM-βA-pSPTF and concentrations of TR-(BRCT)2 ranging from 100-0.05 µM were incubated for two
hours in buffer. The samples were spotted in six replicates due to irregularities in the samples
shape and background interference in some samples.

These samples were analyzed on a

fluorescence scanner, and the fraction bound for each circle was calculated. The scanned sheet
of nitrocellulose and the resulting binding curve from analysis is shown in Figure 6.3. The Kd
determined was 4.8 ± 0.1 µM.

6.4 Discussion
Four peptides were spotted at concentrations ranging from 1000-1 nM, and were spotted
on nitrocellulose.

After drying their diffusion patters were examined with a fluorescence

scanner. It is clearly shown in Figure 6.3 that the three longest peptides did not diffuse readily
across the nitrocellulose even at the lowest concentrations test. In each spot there is clearly
visible both an inner and an outer ring. The fourth and shortest peptide however, shows a single
diffuse circle the same size as the outer ring for all the other peptides. This was present at each
concentration tested indicating this peptide is clearly diffusing even at the highest concentrations
tested. This makes the short, dense negatively charged FAM-β-A-pSPTF peptide potentially
suitable for binding affinity analysis via DRaCALA.
DRaCALA is an attractive alternative to FP and ITC in the measurement of the binding
affinity of the FAM-β-A-pSPTF peptide. First, the small volume of the DRaCALA assay
conserves significant amounts of material. Second, and more importantly, the BRCA1 protein
tends to aggregate at higher concentrations. This aggregation leads to light scattering and
prevents measurement of the upper bounds of the Kd by FP.
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Figure 6.3 DRaCALA of 5-FAM-pSPTF. Analysis of a peptide known to bind to
the BRCA1 (BRCT)2 domain, 5-FAM-pSPTF, was conducted by incubating the
peptide at 20 nM and the TR-(BRCT)2 fusion protein for two hours. 5 µL of each
sample was spotted in six replicates on nitrocellulose A) The resulting spots
analyzed by a fluorescent scanner. B) The binding curve resulting from analysis
of the spots shown in A.
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β-A-pSPTF labeled with FITC has previously been reported to bind to the (BRCT)2
domain of BRCA1 with an affinity of 2.28 ± 0.09 µM.48a Testing the affinity of FAM-β-ApSPTF to TR-(BRCT)2 with DRaCALA produced a binding affinity of 4.8 ± 0.1 µM, which is
quite close to the previously reported value, suggesting that in this case DRaCALA is able to
measure accurately the binding constant. The difference of these values may owe more to the
difference in attached fluorophore or the difference in protein used for the study. It is of course
difficult to draw general conclusions about this technique from a single study, however, this
bodes well for future uses of this technique to measure the binding affinity of short, negatively
charged petpides.

6.5 Experimental
Peptide synthesis. The fluorescently labelled β-amyloid, angiotensin II and 18 mer peptides
were purchased from Anaspec, and no further purification was performed. The β-A-pSPTF
peptide was synthesized using a Liberty Automated Microwave Peptide Synthesizer (CEM). The
peptides were synthesized on Fmoc-PAL-PEG-PS Resin (Applied Biosystems) using N-α-Fmocprotected amino acids (CEM or AAPPTEC) or unnatural N-α-Fmoc protected amino acids
(Chem Impex). After each coupling step a capping step was performed using 20% acetic
anhydride (Fisher Certified ACS), but no capping was performed on the final N-terminal amino
acid to leave the amine free for labelling. The peptide was cleaved from the resin using
trifluoracetic acid (TFA) (Chem Impex)/TIS (Sigma)/DODT (Sigma)/water (92.5:2.5:2.5:2.5)
with incubation at room temperature for 3 hours, and the resin was filtered off. The filtrate
containing the crude peptide was precipitated with cold ether, and collected by centrifugation.
The supernatant was discarded and the peptide was dissolved in CH3CN (Fisher HPLC Grade)
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and water with 10% acetic acid (Fisher certified ACS PLUS) (1:1) followed by freezing and
lyophilization.

The peptide was then purified by reverse phase HPLC using a Shimadzu

Prominence system with a Vydac (218TP C18 5μ) column with 0.1% TFA in water (A) and
CH3CN (B) as the mobile phase with monitoring at 443 nm.
Spotting Peptides on Nitrocellulose. All peptides were dissolved in PBS (137 mM NaCl, 2.7
mM KCl, 10 mM phosphate, pH 7.4) and diluted to the indicated concentrations. 5 µL was
spotted of each was spotted onto dry-untreated nitrocellulose (Bio-Rad Trans Blot Transfer
Medium) at least 2 cm apart. Spots were allowed to dry for 20 minutes and scanned on a
Typhoon 9410 Variable Mode Imager (Amersham Biosciences) with an excitation wavelength of
488 nm. Resulting images were analysed with ImageQuant 5.1 software.
DRaCALA. Protein was mixed with 20 nM radiolabeled nucleotide in buffer (300 mM NaCl,
2.7 mM KCl, 10 mM phosphate, pH 7.4) and allowed to incubate for 2 hours at room
temperature. These mixtures were pipetted (5 μL) onto dry untreated nitrocellulose (BioRad
Trans Blot Transfer Medium) at least 1 cm apart in six replicates and allowed to dry completely
before scanning on a Typhoon 9410 Variable Mode Imager (Amersham Biosciences) with an
excitation wavelength of 488 nm.

Resulting images were analysed with ImageQuant 5.1

software.

6.6 Summary
Four fluorescently labeled peptides were tested for their suitability for use as the ligand in
a DRaCALA assay. This was measured simply by spotting 5 µL of serially diluted peptide
solutions onto nitrocellulose, and examining the pattern of diffusion on a fluorescence scanner.
Only the shortest peptide, which also had the densest negative charge, freely diffused onto the
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nitrocellulose. This peptide was used in a DRaCALA assay to determine its binding affinity to
the (BRCT)2 domain of BRCA1. A value of 4.9 ± 0.1 µM was obtained, which is quite close to
a previous literature report of 2.28 ± 0.09 µM.48a This technique will not be generalizable to all
peptides, but has shown here to work in special cases.

Future Directions. Although this technique may not be applicable to all peptides, it did help us
confirm the affinity of a peptide that was difficult to determine via other methods. This might be
a viable option for these special cases, but is not likely suited for hydrophobic and perhaps
overall neutral peptides. Preliminary data (not shown) indicates that larger negatively charged
peptides diffuse readily on nitrocellulose, and that positively charged peptides like poly-arginine
diffuse well on polyethyleneimine (PEI) membranes. Additional study is required to confirm
these conclusions.
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Overall Summary and Conclusions

Inhibitors of the BRCA1 C-Terminal (BRCT)2 domain have been sought after, yet many
of the traditional routes to drug discovery have failed to produce viable inhibitors.

Even

successful attempts to design peptides that bind to the (BRCT)2 domain have been unable to
produce a promising drug candidate due to reliance on the incorporation of a phosphoserine.
Peptide libraries have previously proven themselves to be a powerful tools in selecting peptides
that bind to protein surfaces, and an important aspect of this has been their large diversity which
adds great power to these techniques. Can this technique be used to overcome the phosphate
“requirement?” We proposed that the large diversity (>1013 members) of an mRNA display
library that does not contain phospho-amino acids could be applied to the selection of a nonphsophorylated BRCA1 inhibitor.
In addition to the large number of library members, unnatural amino acids (UNAAs)
were also used in an attempt to increase the chemical diversity of the library.

This was

accomplished via substation of some of the 20 naturally occurring amino acids with unnatural
analogues. This is possible because these libraries are constructed within a PURE translation
system that allows for control of the in vitro translation reaction components. By simply leaving
out a natural amino acid, we can simply substitute a similar UNAAs that will be incorporated by
the translation machinery instead. Six UNAAs were found that work well together and were
used in translation of the peptide library.
The library peptides consisted of a fixed Met-Cys followed by a 12-amino acid random
region encoded by an NNB codon (where N = A, C, T, or G and B = C, T, or G). This decreases
the number of stop codons, as well as enriches the number of cysteines found in the random
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region so that 40% of the library members should have a second cysteine. This is important as
the library will be subject to cyclization with dibromoxylene that will act as a covalent linker
selectively between two cysteines.

This will hopefully result in peptides with a more rigid

peptide scaffolds that may lead to tighter peptide binding due to decreased entropic cost in
binding.
The selection was conducted over eight rounds against GST-(BRCT)2 fusion protein
immobilized on magnetic glutathione beads. In all but the first round, a pre-clearing step was
conducted against immobilized GST. The selection enrichment was monitored via the
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S-Met

incorporated in the peptides and calculated for each round. In round 7 a spike in enrichment was
observed followed by the beginning of a plateau in round 8. The surviving peptides were
sequenced and in the resulting sequences, seven peptides recurred more than once and comprised
more than 80 % of the sequences. These sequences were assigned numbers 8.1 to 8.7 based on
their frequency in the sequencing results. Each sequence contains a D/E-X-X-F motif, which is
analogous to the pS-X-X-F motif known to bind the BRCA1 (BRCT)2 domain where the D and
E are known phosphoserine mimetics. This was a promising result indicating the peptide likely
binds in known binding groove. UNAAs that were selected were primarily the Phe analog (4fluoro-phe) and the Arg analog (canavanine). It was interesting however, than none of the
peptide sequences contained a second cysteine in the random region. MS/MS analysis showed
that the dibromoxylene is instead forming a sulfonium ion linkage with the fixed methionine.
An initial ranking of the 7 peptide families in both their linear and cyclized (treated with
dibromoxylene) forms was achieved with a competitive fluorescence polarization (FP) study
with a peptide (FITC-β-A-pSPTF) known to inhibit the (BRCT)2 domain. However, these tests
are not completely indicative of what was selected because one of the UNAAS, canavanine, was
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unable to be incorporated in solid phase peptide synthesis, so arginine was substituted instead.
Upon this initial ranking it was clear that linear peptide 8.6 (with the sequence
MCTIDF26DEYRF26KRT) had the highest affinity with peptides 8.1 and 8.5 just behind with
approximately two-fold lower affinity.
To further investigate how this non-phosphorylated peptide binds to the (BRCT)2
domain, a series of truncated mutants were tested in the same FP assay. The core domains
(DEYRF26 and F26DEYRF26) were not sufficient to observe binding to the domain. C-Terminal
(MCTIDF26DERYF26) and N-terminal (DEYRF26RKT) deletions revealed that the contribution
of the N-terminal amino acids are much more significant that the C-terminal amino acids due to
over an order of magnitude decrease compared to the mere two-fold decrease in affinity observed
with the C-terminal deletion. Additionally deletion of the fixed MC at the N-terminus showed an
approximately two-fold decrease affinity. This seems to indicate that the full length peptide is
necessary to achieve the highest binding affinity.
Further mutational studies were conducted to investigate the importance of individual
amino acids in the sequence of peptide 8.6. First, mutations of the E8 and F11 to A both nearly
abolished binding altogether indicating that these amino acids are necessary, but not sufficient
for binding. The contrary mutation, replacing E8 with a pS, surprisingly had only a three-fold
increase in binding affinity when previous pS to E mutations resulting in a multiple order of
magnitude decrease in affinity. Because of this observation, we wondered if the N-terminal
amino acids would still be as important in the presence of the pS containing peptide. This Nterminal truncated pS peptide had a very slight increase in affinity leading to the conclusion that
the N-terminal amino acids are no longer necessary when the pS is present in the E-X-X-F motif.
Additionally, replacement of the two F26 amino acids with F resulted in a two-fold increase in
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binding affinity. The question of what role canavanine would play in these peptides is still open,
but for now the all-natural (AN 8.6) will be used in future study.
One interesting variation between the 7 peptides found in selection is where the D/E-XX-F was positioned in the random region. The two highest affinity hits 8.6 and 8.1 had very
different position of this core motif. With the core boing closer to the C-terminus in peptide 8.6
and closer to the N-terminus in peptide 8.1, it was hypothesized that perhaps combining these
sequences into longer peptides could result in a peptide that covers more of the protein surface
and has a higher affinity. However, after making three different hybrid combinations, none of
these peptides had an affinity higher than peptide 8.6. Mutations of individual amino acids of
peptide 8.6 to amino acids found in the same position around the core domain of peptide 8.1
were also investigated. Although neither mutation of E8D, or Y9F and R10I achieved a peptide
with a higher affinity than AN 8.6, they were less than a two-fold decrease in affinity. The
mutation of D7N was nearly a neutral mutation.
Isothermal titration calorimetry (ITC) was conducted on peptides 8.6, AN 8.6, 8.6 E8pS
and 8.6 E8pS 8-14. The affinities determined from ITC were found to be very similar to those
determined by FP with AN 8.6 having a Kd of 1 µM. No differences in binding mechanism
could be determined, but each binding interaction was enthalpically driven.
Although these peptides seem to inhibit the (BRCT)2 domain in vitro, AN 8.6 was tested
for its ability to inhibit binding interactions in cell lysate. In a pull-down western experiment,
binding of CtIP-myc in cell lysate was able to be inhibited from binding to immobilized GST(BRCT)2 fusion in a dose-dependent manner. At concentrations of 50 µM in solution, this
protein-protein interaction (PPI) was almost completely abrogated.
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This work has shown a means of developing a non-phosphorylated peptide that can
inhibit a PPI that has been previously thought to be ‘un-druggable’ due to the “requirement” of a
phosphate. It has shown to be able to inhibit its target PPI in cell lysate, but there is still much
work left to be done. With a 1 µM affinity, it is unclear as to whether or not it will be a viable
inhibitor in cells. Preliminary data of cellular overexpression is promising, but can sufficient
quantities of AN 8.6 be delivered exogenously? Various cell-penetrating techniques can be
applied, but such an effort would also be aided by an increased affinity peptide. From this point,
perhaps rational design would be a good place to start. Preliminary crystal structure data has
given us some information about how this peptide binds, but can this be peptide be optimized
from this structural information?
Another possibility is conducting another selection.

It was found that a linear

conformation was preferred, and the current selection was limited to a 12 amino acid random
region. Would a longer peptide be beneficial? Throughout this work, it has been assumed that
this peptide is in a floppy, linear conformation in solution, and remains linear upon binding, but
what is its actual conformation in solution? If there is helical propensity, is it possible that
altering the sequence to change this propensity could increase the affinity? What about another
selection with a semi-random region based on the crystal structure data? Is optimization even
necessary to begin to use this peptide as a tool? With an all-natural amino acid sequence, it
could be over-expressed in cells to study BRCA1 inhibition. This work has also opened up the
possibility of performing selections on other (BRCT)2 domains. Each of these domains are
known to interact with phosphoproteins, and in theory could be targeted with the same mRNA
display library approach.
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There are many directions that this work could continue, and in the grand tradition of
scientific investigation it has opened more questions that it has answered. However, it did answer
some important questions. We were able to use the power in numbers to find a non-phosphate
containing inhibitor of BRCA1’s (BRCT)2 domain, and demonstrate that this inhibitor could be
used successfully in cell lysate to disrupt a PPI. As PPIs become increasingly viewed as viable
drug targets, studies like this one may help pave the way for a new method of drug design.
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